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Gene-drug interactions and the evolution of antibiotic resistance 
 
Abstract 
    The evolution of antibiotic resistance is shaped by interactions between genes, 
the chemical environment, and an antibiotic's mechanism of action. This thesis explores these 
interactions with experiments, theory, and analysis, seeking a mechanistic understanding of 
how different interactions between genes and drugs can enhance or constrain the evolution of 
antibiotic resistance. 
 
  Chapter 1 investigates the effects of the chemical decay of an antibiotic. Tetracycline 
resistant and sensitive bacteria were grown competitively in the presence of tetracycline and 
its decay products. Antibiotic decay did not only remove selection for resistance, but long-
lived decay products favored tetracycline sensitivity by inducing costly drug efflux pumps in 
the resistant strain. Selection against resistance by antibiotic-related compounds may 
contribute to the coexistence of drug-sensitive and resistant bacteria in nature. 
 
  Chapter 2 investigates how genetic interactions can favor particular combinations of 
resistance-conferring mutations. All possible combinations of a set of trimethoprim 
resistance-conferring mutations in the drug's target gene were constructed and phenotyped. 
Incompatibilities between mutations arose in a high-order, not pairwise, manner. One 
mutation was found to induce this ruggedness and create a multi-peaked adaptive landscape. Professor Roy Kishony    Adam Christopher Palmer 
  iv
  Chapters 1 and 2 observed that non-optimal expression of a drug resistance gene or a 
drug's target could compromise antibiotic resistance. Chapter 3 broadly characterizes non-
optimal gene expression under antibiotic treatment, using a functional genetic screen to 
identify over one hundred pathways to antibiotic resistance through positive and negative 
changes in gene expression. Genes with the potential to confer antibiotic resistance were 
found to often go unused during antibiotic stress. The optimization of gene expression for 
drug-free growth was found to cause non-optimal expression under drug treatment, creating 
a situation where regulatory mutations can confer resistance by correcting errors in gene 
expression. 
 
  Chapter 4 investigates whether it is beneficial to up-regulate the genes encoding 
antibiotic targets when they are inhibited. Drug target genes were quantitatively over-
expressed, and drug resistance was found to not always increase, but alternatively to remain 
unchanged or even decrease. These diverse effects were explained by simple models that 
consider toxicity arising from gene over-expression, and mechanisms of drug action in which 
drugs induce harmful enzymatic reactions. 
   v
Table of contents 
Chapter 1. 
Chemical decay of an antibiotic inverts selection for resistance ......................................... 1 
Methods ....................................................................................................................................... 15 
References .................................................................................................................................... 19 
 
Chapter 2. 
A multi-peaked adaptive landscape arising from high-order genetic interactions ....... 22 
Methods ....................................................................................................................................... 44 
References .................................................................................................................................... 48 
 
Chapter 3. 
Diverse pathways to drug resistance by changes in gene expression ............................... 50 
Methods ....................................................................................................................................... 79 
References .................................................................................................................................... 86 
 
Chapter 4. 
The dependence of antibiotic resistance on target expression .......................................... 89 
Methods .....................................................................................................................................  103 
References ..................................................................................................................................  107  
 
Supplementary Material. 
Chapter 1 ...................................................................................................................................  110 
Chapter 2 ...................................................................................................................................  128 
Chapter 3 ...................................................................................................................................  130 
Chapter 4 ...................................................................................................................................  154 
References ..................................................................................................................................  177  vi
 
 
 
 
 
 
A cell can regulate some genes perfectly all of the time, and all genes perfectly some of the time, 
but a cell can not regulate all genes perfectly all of the time. 
 
-with apologies to Abraham Lincoln 
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Chapter 1. 
Chemical decay of an antibiotic inverts selection for resistance 
 
Adam C. Palmer1, Elaine Angelino1, Roy Kishony1,2  
1Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115. 
2School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138. 
 
Antibiotics are often unstable, decaying into a range of compounds with potential biological 
activities.  We found that as tetracycline degrades, the competitive advantage conferred to 
bacteria by resistance to it not only diminishes, but reverses to become a prolonged 
disadvantage due to the activities of more stable degradation products.  Tetracycline decay 
can therefore lead to net selection against resistance, which may help explain the puzzling 
coexistence of sensitive and resistant strains in natural environments. 
 
   2
More than half of all known antibiotics are secreted by soil bacteria (Kieser et al., 2000), 
mediating communication (Fajardo and Martinez, 2008; Linares et al., 2006; Yim et al., 2007), 
metabolism (Dantas et al., 2008; Price-Whelan et al., 2006) and warfare (Walsh, 2003). While 
resistance to these naturally-occurring antibiotics is prevalent in the soil environment, the 
genes conferring resistance do not seem to take over and fixate in these natural populations; 
instead resistant and sensitive bacterial strains coexist (D'Costa et al., 2006). It is therefore 
likely that while antibiotics select for resistant strains, other natural mechanisms might exist 
which select against resistance. Indeed, several natural chemicals are known to specifically 
inhibit growth of strains resistant to certain antibiotics (Bochner et al., 1980; Halling-
Sorensen et al., 2002). The ability of any compound to select for or against resistance depends 
not only on the selective pressure it exerts, but also on the duration of its activity, determined 
by its chemical stability. Many antibiotics are short-lived in the natural environment; they 
decay to an assortment of chemical species which may be more stable than the precursor 
drug, and may therefore have significant ecological impacts. Thus, competition between 
antibiotic resistant and sensitive strains may be influenced both by the short-term effect of an 
antibiotic and by the potential long-term effects of its degradation products (Figure 1.1a). 
Here we ask how the chemical decay of tetracycline influences selection for resistant strains. 
Tetracycline is widely used clinically (Chopra et al., 1992) and agriculturally(Sarmah et al., 
2006), its major degradation pathway is well characterized (Yuen and Sokoloski, 1977), and 
its decay products are found in soil, wastewater, and market tetracyclines (Jia et al., 2009; 
Sarmah et al., 2006; Walton et al., 1970). One of its decay products, anhydrotetracycline, is 
known to preferentially inhibit the growth of bacteria carrying the Tn10 tetracycline   3
resistance determinant, by binding the tetR regulator to induce expression of the costly tetA 
efflux pump (Eckert and Beck, 1989; Lederer et al., 1996; Moyed et al., 1983; Nguyen et al., 
1989). We investigated the selective advantage/disadvantage of resistance throughout the 
degradation process, by directly competing fluorescently labeled tetracycline resistant and 
sensitive strains of Escherichia coli. 
 
Tetracycline (Tet) undergoes reversible epimerization to epitetracycline (ETC) and also 
irreversible dehydration to anhydrotetracycline (ATC), with both epimerization and 
dehydration yielding epianhydrotetracycline (EATC) (Yuen and Sokoloski, 1977) (Figure 
1.1b). To accelerate the degradation process to convenient timescales we exposed tetracycline 
to phosphoric acid and high temperatures (Yuen and Sokoloski, 1977); Methods). At different 
time-points of exposure to these degrading conditions (tdeg), samples of the chemical reaction 
were taken and the reaction was stopped by shifting to neutral pH and freezing. To track the 
abundance of tetracycline and its degradation products over time, we measured the 
absorbance spectrum of each sample and compared it to the spectra of the individual 
compounds (Supplementary Figure 1.1). A previously established kinetic model (Yuen and 
Sokoloski, 1977), extended to account for the loss of the degradation products at very long 
timescales, was fully consistent with the spectral data (Figure 1.1c; Methods and 
Supplementary Figs. 1.2-1.4). 
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Figure 1.1. Tetracycline degrades into a range of longer lived compounds, with potential 
ecological impacts on selection for resistance.  a, While an antibiotic selects for strains 
resistant to it, it is not clear what selective pressure is imposed by its soup of degradation 
products. b, Tetracycline degrades into a range of bioactive compounds, which themselves 
slowly decay further. c, Tetracycline decay products have different concentration profiles 
through time. Degradation is accelerated by pH of 1.5 and temperature of 75°C (Yuen and 
Sokoloski, 1977). Shaded areas in this stacked plot represent the kinetic model of (Yuen and 
Sokoloski, 1977) with a correction for long-term decay (Methods). Points are estimated 
fractions of Tet and its degradation products, obtained by fitting the spectra of pure 
compounds to a spectrum of the degraded Tet solution at each individual timepoint 
(Methods). ATC and EATC are not well distinguished spectrally, and so are plotted as their 
sum. These fitted points confirm the consistency of our samples with the kinetic model of 
(Yuen and Sokoloski, 1977).    5
 
 
Figure 1.1. Tetracycline degrades into a range of longer lived compounds, with potential 
ecological impacts on selection for resistance. (Continued) 
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To measure the selective pressure for tetracycline resistance imposed by samples of Tet that 
had been exposed to degrading conditions for different times, we used a fluorescence-based 
competition assay between resistant and sensitive E. coli (Chait et al., 2007; Hegreness et al., 
2006). Matching Tet resistant (TetR) and sensitive (TetS) strains were generated by supplying 
MG1655 with a plasmid carrying the tetR-tetA genes from the Tn10 transposon, or with the 
non-resistant parental plasmid, respectively (Lenski et al., 1994). These TetS and TetR strains 
were differentially labeled with chromosomally encoded cyan and yellow fluorescent proteins; 
pairs of strains were constructed in both dye permutations. Direct competition between the 
strains, as well as high-resolution measurements of their individual growth rates (Kishony 
and Leibler, 2003; Yeh et al., 2006), showed equal fitness of the TetS and TetR strains in the 
absence of Tet (Supplementary Figure 1.5). To measure selection for or against resistance, 
TetS and TetR strains were mixed 1:1 in fresh media, a sample of untreated or degraded Tet 
was added, and the cultures were grown overnight to stationary phase; the final ratio of 
sensitive cell count (NTet
S) to resistant cell count (NTet
R) was then measured by flow cytometry 
(Figure 1.2a). 
 
While Tet strongly selects in favor of resistance, we found that its cocktail of degradation 
products actually shows selection in favor of sensitivity (Figure 1.2c,d, trajectory 1). Solutions 
of Tet with little or no exposure to degrading conditions (tdeg < ~50 min), applied at high 
concentrations (1000 ng/mL), strongly favored the growth of resistant bacteria. However, 
following substantial degradation (tdeg  >  ~50 min), not only did the loss of Tet abolish 
selection for resistance, but the accumulation of its degradation products caused strong   7
selection against resistance (Figure 1.2c,d, change from red to green along trajectory 1; similar 
results are seen with chromosomally-integrated tetracycline resistance, in the presence of the 
naturally occurring compound fusaric acid, Supplementary Figure 1.6). Importantly, while 
the initial selection in favor of resistance was short lived, the subsequent selection in favor of 
sensitivity lasted for much longer times, and had not weakened much even at the latest time 
point of tdeg~450 min. 
 
We consider the full ecological impact of an antibiotic as the selective pressure of the 
antibiotic and its degradation products integrated over time. This integrated selective 
pressure is represented by the area between the curve of the fold changes in log(NTet
S / NTet
R) 
and the line log(NTet
S / NTet
R) =0 (no selection) (Figure 1.2d). When degradation is the primary 
means of loss (trajectory 1), the initial selection for resistance by Tet is greatly outweighed by 
the subsequent longer selection against resistance by more stable degradation products 
(Figure 1.1c). 
 
In a natural scenario, an initial drug dosage may not only be lost due to degradation, but also 
due to dilution, or diffusion (Figure 1.2b). To account for dilution in addition to degradation, 
we applied our TetR-TetS competition assay across a 2D gradient created by serial dilution of 
each of the time samples of the degradation reaction (Figure 1.2c). Dilution of the drug and 
its degradation products can profoundly affect the overall selection pressure: if Tet loss is 
dominated by dilution, degradation products do not appear at substantial concentration and 
so the selective pressure of the initial compound, Tet, is dominant, favoring resistance (Figure   8
1.2c,d, trajectory 3). In these conditions the net selection is in favor of resistance, 
demonstrating that dilution can eliminate the ability of degradation products to invert the 
selective pressure. Tet clearance in the clinical setting and in treatment of farm animals is 
dominated by dilution rather than degradation (Kelly and Buyske, 1960), consistent with the 
selective advantage of resistance in these settings (Levy et al., 1976). 
 
More generally, we envision that in the environment a drug may be lost simultaneously by 
both degradation and dilution. An environment initially containing a fixed dose of Tet will 
then move through different chemical environments along a linear trajectory across Figure 
1.2c, with a slope defined by the ratio between the dilution rate and the degradation rate 
(-λdil/λdeg, where λdil, λdeg are the reciprocals of the drug’s half-life due to dilution and 
degradation, respectively). We find that when both degradation and dilution are active, 
selective pressure can vary over time in a complex non-monotonic manner. For example, in 
trajectory 2 (Figure 1.2c,d), the initial selection in favor of resistance is followed by selection 
against resistance, but then at low concentrations of degradation products weak selection in 
favor of resistance returns. Since degradation products select in opposing directions 
depending upon their concentration, net selection depends non-trivially upon both the 
means of loss and the initial concentration of antibiotic (Supplementary Figure 1.7). 
 
We next asked to what extent these complex trajectories of selective effects, exerted 
throughout Tet decay, can be rationalized in terms of the individual selective pressures 
exerted by the drug and each of its degradation products. We measured the effect on the TetS-  9
TetR competition imposed by Tet, ETC, ATC and EATC as a function of concentration 
(Supplementary Figure 1.8). We found that each of the degradation products has a different 
selective impact and that selection against resistance is mediated by ATC. This observation is 
consistent with the known action of ATC as a strong inducer of the costly tet operon (Eckert 
and Beck, 1989; Lederer et al., 1996) and adds to the growing evidence of signaling roles for 
antibiotics (Goh et al., 2002; Linares et al., 2006; Yim et al., 2007). In principle, ‘non-additive’ 
interactions may be present in drug combinations, producing effects not explainable by the 
sum of individual drug effects. We adopt the Bliss definition of additivity, where the effect of 
drugs in combination is equal to the multiplication of their individual effects (Bliss, 1939). To 
test for non-additive drug interactions, we measured selective pressures across a 2D gradient 
of Tet vs. a 1:1 mixture of ATC and EATC, chosen to approximately represent the chemical 
environments encountered following Tet decay (the epimerization is a relatively fast reaction 
leading to nearly equal amounts of ATC and EATC at late times, Figure 1.1c). We found that 
Bliss additivity reproduced all features of the measured 2D gradient, with quantitative 
deviations only at high drug concentrations, suggesting that interactions amongst Tet and the 
decay products ATC and EATC are primarily additive (Supplementary Figure 1.9). 
 
An additive model of the selective pressures throughout Tet degradation and dilution was 
then constructed from the kinetic model of chemical composition (Figure 1.1c, 
Supplementary Figure 1.3) and the selective effects of each of the individual compounds 
(Supplementary Figure 1.8). This additive model shows very good qualitative and quantitative 
agreement with the measured selective pressures along trajectories 1, 2 and 3 (Figure 1.2d,   10
compare dashed line with filled area). Selection by Tet and its degradation products can 
therefore be understood as the additive sum of the effects of each of the compounds. 
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Figure 1.2. Tetracycline degradation inverts the overall selective advantage of resistant 
strains. a, To measure selection for/against resistance by degraded tetracycline solution, a 
sample of the degradation reaction is taken at timepoint tdeg and is added to a 1:1 mixture of 
resistant (TetR) and sensitive (TetS) cells inoculated into fresh media. Fluorescent labels (YFP 
or CFP) allow changes in the ratio NTet
S / NTet
R  to be measured by flow cytometry, after 
overnight competition. b, Loss of the initial drug can occur by either degradation to alternate 
compounds (across x-axis), or by dilution (down y-axis). c, Selective pressure in favor (red) or 
against (green) resistance as a function of the degradation time tdeg and dilution (axes 
definitions match panel b). Black points mark measurements, between which the color map is 
interpolated. Numbered black lines are trajectories representing Tet loss by degradation alone 
(1), dilution alone (3), or a combination of both with respective rates λdeg and λdil (2). d, 
Selective pressure changes over time as Tet is lost along the three trajectories of panel c. 
Shaded areas represent the integrated selective pressure in favor (red) or against (green) 
resistance. The time axis is normalized by net rate of Tet loss (λdeg + λdil). Dotted black lines 
are an additive model of selective pressure, constructed by summing the changes in log(NTet
S / 
NTet
R) produced by each of the individual compounds (Supplementary Figure 1.8), given their 
concentrations from the kinetic model of Tet decay (Figure 1.1c).   12
 
 
 
 
Figure 1.2. Tetracycline degradation inverts the overall selective advantage of resistant 
strains. (Continued)   13
In the natural environment, antibiotics are not static - a single drug can decay into a range of 
compounds, each accumulating and degrading with different kinetics and displaying different 
selective effects. The simple additive sum of the effects of each of the degradation products 
can lead to complex, non-monotonic, patterns of selections for and against resistance. 
Consequently, the net evolutionary impact of a drug depends upon the manner of its eventual 
loss from the environment. When Tet loss is dominated by degradation, the initial selection 
for resistance by tetracycline can be substantially outbalanced by the prolonged selection 
against resistance imposed by its longer lived degradation products. While these results were 
demonstrated for accelerated degradation of tetracycline, they depend on relative, rather than 
absolute, stabilities of the drug and its degradation products, and therefore may be of 
relevance also to the natural environment. Interestingly, ATC is a biosynthetic precursor to 
Tet in the drug producing microbes (McCormick et al., 1968), and induces Tet efflux pump 
expression prior to the imminent production of the drug. This provides an evolutionary 
rationale for non-toxic drug derivatives to be potent inducers of resistant genes. It will be 
interesting to test the selective effect of decay of other drugs on various resistance 
mechanisms and via multiple decay pathways; different decay pathways will produce different 
metabolites, which could be affected by the environment and even by other surrounding 
microbes (Dantas et al., 2008). Selection against resistance by antibiotic decay may help 
explain the puzzling coexistence of antibiotic resistant and sensitive microbial strains in the 
natural soil environment.   14
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Methods 
Strains and Media 
Fluorescently labeled strains MC4100-YFP and MC4100-CFP, described 
previously(Hegreness et al., 2006), were transformed with plasmid pBT107-6A to create a Tet 
resistant strain, or with the parent plasmid pACYC177 to create a Tet sensitive strain. 
pBT107-6A carries the Tn10 tetracycline resistance determinant, with a tetA promoter down-
mutation which has been demonstrated to provide higher fitness in the presence of 
10 μg.mL−1 Tet than either stronger or weaker promoters(Daniels and Bertrand, 1985; Lenski 
et al., 1994). 
 
All fitness measurements were performed in M63 minimal medium (2  g.L–1 (NH4)2SO4, 
13.6 g.L–1 KH2PO4, 0.5 mg.L–1 FeSO4•7H2O) supplemented with 0.2% glucose, 0.1% casamino 
acids, 1mM MgSO4 and 1.5 μM thiamine, and also 100 μg.mL–1 ampicillin and 50 μg.mL–1 
kanamycin for the maintenance of pACYC177 based plasmids. Drug solutions were made 
from powder stocks (Sigma, Vetranal analytical standard: tetracycline hydrochloride, #3174; 
epitetracycline hydrochloride, #37918; anhydrotetracycline hydrochloride, #37919; 
epianhydrotetracycline hydrochloride, #37921) dissolved in ethanol, with drug gradients 
made by serial dilution in M63 medium. 
   16
Tetracycline degradation 
Powdered tetracycline was dissolved in 1M phosphoric acid, pH 1.5, at 400μg/mL. Aliquots 
were incubated at 75°C and transferred to ice at various time points. These frozen samples 
were diluted 40× into M63 media for fitness assay, or into water for spectroscopy. 
 
Spectroscopy and determination of chemical composition from spectra 
All spectra were recorded at 10 μg/mL in aqueous solution, on a Cary 300 spectrophotometer 
(Varian). The kinetic model of (Yuen and Sokoloski, 1977), modified to include a reaction for 
the slow further decay of Tet degradation products with rate constant kloss, successfully fitted 
the time series of spectra (Supplementary Figs. 2, 3) using all other rate constants as 
previously measured by HPLC (Yuen and Sokoloski, 1977). Allowing all rate constants to be 
simultaneously fitted to all spectra produces only a 2% reduction in the sum of square errors; 
the previously measured parameters have values that minimize errors in the spectral 
alignment, for all parameters for which a well defined minimum exists (Supplementary 
Figure 1.4, Supplementary Table 1.1). Species concentrations were estimated from spectra at 
individual timepoints (points in Figure 1.1c) by numerically searching for the local minimum 
in alignment error over the characteristic wavelength ranges 250-290nm and 325-400nm, 
starting from the composition predicted by the kinetic model; numerical minimization was 
performed by the FindMinimum function of Mathematica 7.0 (Wolfram).  
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Competitive fitness assay 
Selection between resistant and sensitive cells by a particular chemical environment was 
measured by mixing stationary phase cultures of resistant and sensitive strains at 1:1 ratio, 
and further diluting 1:100 into fresh media containing the chemical environment of interest. 
Competitive growth occurred throughout 24 hours of growth with shaking at 30°C in clear, 
flat bottomed 96-well plates (Corning #3595), sealed with adhesive lids (Perkin Elmer 
#6005185). Sensitive and resistant cells were differentially labeled with a chromosomally 
integrated YFP or CFP gene driven by the Plac promoter, which is constitutive in the lacI 
strains used here. To obtain stronger fluorescence signals, the stationary phase cultures 
obtained after 24 hours of competition were subcultured 1:100 into fresh drug-free media, 
and grown as before for between 90 and 180 minutes, before the ratio of yellow to cyan 
fluorescent cells was counted by flow cytometry (Becton Dickinson LSRII; CFP excited at 
405nm, emission detected through 505LP and 525/550nm filters; YFP excited at 488nm, 
emission also detected through 505LP and 525/550nm filters). Plating and colony counting of 
selected wells confirmed that the final subculturing and brief growth did not alter the ratio 
NTet
S / NTet
R, within the margin of error of counting 200 - 500 colonies per plate. The selective 
pressures presented in Figure 1.2c and Supplementary Figure 1.8 are the average of two 
experiments, one where fluorescent labels were swapped between TetS and TetR strains. No 
substantial difference was detected between dye-swaps, indicating that the use of differential 
dyes does not influence NTet
S / NTet
R ratio (Supplementary Figure 1.10). At least 16 wells per 
plate were drug-free, for precise measurement of NTet
S / NTet
R ratio in non-selective conditions.   18
The mean ratio NTet
S / NTet
R (mean determined on log scale) in these drug-free wells provided 
the reference point, determined separately for each plate, for the fold change in NTet
S / NTet
R. 
For Supplementary Figure 1.6, fusaric acid was applied uniformly across the plate, including 
reference wells, such that any selection (changes in NTet
S / NTet
R) due solely to fusaric acid is 
removed in the normalization to reference wells. Thus, the selective effects seen in 
Supplementary Figure 1.6 are due to tetracycline and its degradation products, or drug-drug 
interactions between these compounds and fusaric acid. Sample flow cytometry data from 
three points in Figure 1.2c are presented in Supplementary Figure 1.11, demonstrating 
selection for, against, and neutral with respect to resistance. 
 
Growth rate assay 
TetS and TetR strains were transformed with a plasmid-borne, constitutively expressed 
bacterial bioluminescence operon(Kishony and Leibler, 2003). Photon counting of growing 
bioluminescent cultures allows precise measurements of cell densities over many orders of 
magnitudes (e.g. Supplementary Figure 1.5). Cultured were grown in black 96-well plates 
(Corning #3792) sealed with clear adhesive lids (Perkin Elmer #6005185). Readings were 
made by a Perkin Elmer TopCount NXT Microplate Scintillation and Luminescence Counter, 
stored in a 30°C room at 70% humidity, with duplicate 1 second readings per well. Wells 
contained 100μL of media inoculated with approximately 10 to 100 cells from fresh -80°C 
frozen cultures. Growth rate is the slope of the logarithm of photon counts per second (c.p.s.), 
and is taken from the line of best fit spanning the fastest 5 doublings.   19
References 
Bliss, C.I. (1939). The toxicity of poisons applied jointly. Ann Appl Biol 26, 585-615. 
Bochner, B.R., Huang, H.C., Schieven, G.L., and Ames, B.N. (1980). Positive selection for loss of 
tetracycline resistance. J Bacteriol 143, 926-933. 
Chait, R., Craney, A., and Kishony, R. (2007). Antibiotic interactions that select against resistance. 
Nature 446, 668--671. 
Chopra, I., Hawkey, P.M., and Hinton, M. (1992). Tetracyclines, molecular and clinical aspects. J 
Antimicrob Chemother 29, 245-277. 
D'Costa, V.M., McGrann, K.M., Hughes, D.W., and Wright, G.D. (2006). Sampling the antibiotic 
resistome. Science 311, 374--377. 
Daniels, D.W., and Bertrand, K.P. (1985). Promoter mutations affecting divergent transcription in the 
Tn10 tetracycline resistance determinant. J Mol Biol 184, 599--610. 
Dantas, G., Sommer, M.O., Oluwasegun, R.D., and Church, G.M. (2008). Bacteria subsisting on 
antibiotics. Science 320, 100-103. 
Eckert, B., and Beck, C.F. (1989). Overproduction of transposon Tn10-encoded tetracycline resistance 
protein results in cell death and loss of membrane potential. J Bacteriol 171, 3557--3559. 
Fajardo, A., and Martinez, J.L. (2008). Antibiotics as signals that trigger specific bacterial responses. 
Curr Opin Microbiol 11, 161-167. 
Goh, E.B., Yim, G., Tsui, W., McClure, J., Surette, M.G., and Davies, J. (2002). Transcriptional 
modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl 
Acad Sci U S A 99, 17025-17030. 
Halling-Sorensen, B., Sengelov, G., and Tjornelund, J. (2002). Toxicity of tetracyclines and tetracycline 
degradation products to environmentally relevant bacteria, including selected tetracycline-resistant 
bacteria. Arch Environ Contam Toxicol 42, 263-271. 
Hegreness, M., Shoresh, N., Hartl, D., and Kishony, R. (2006). An equivalence principle for the 
incorporation of favorable mutations in asexual populations. Science 311, 1615--1617.   20
Jia, A., Xiao, Y., Hu, J., Asami, M., and Kunikane, S. (2009). Simultaneous determination of 
tetracyclines and their degradation products in environmental waters by liquid chromatography-
electrospray tandem mass spectrometry. J Chromatogr A 1216, 4655-4662. 
Kelly, R.G., and Buyske, D.A. (1960). Metabolism of tetracycline in the rat and the dog. J Pharmacol 
Exp Ther 130, 144-149. 
Kieser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., and Hopwood, D.A. (2000). Practical Streptomyces 
Genetics, 1st edn (John Innes Foundation, Norwich, UK). 
Kishony, R., and Leibler, S. (2003). Environmental stresses can alleviate the average deleterious effect 
of mutations. J Biol 2, 14. 
Lederer, T., Kintrup, M., Takahashi, M., Sum, P.E., Ellestad, G.A., and Hillen, W. (1996). Tetracycline 
analogs affecting binding to Tn10-Encoded Tet repressor trigger the same mechanism of induction. 
Biochemistry 35, 7439--7446. 
Lenski, R.E., Souza, V., Duong, L.P., Phan, Q.G., Nguyen, T.N., and Bertrand, K.P. (1994). Epistatic 
effects of promoter and repressor functions of the Tn10 tetracycline-resistance operon of the fitness of 
Escherichia coli. Mol Ecol 3, 127--135. 
Levy, S.B., FitzGerald, G.B., and Macone, A.B. (1976). Changes in intestinal flora of farm personnel 
after introduction of a tetracycline-supplemented feed on a farm. N Engl J Med 295, 583--588. 
Linares, J.F., Gustafsson, I., Baquero, F., and Martinez, J.L. (2006). Antibiotics as intermicrobial 
signaling agents instead of weapons. Proc Natl Acad Sci U S A 103, 19484-19489. 
McCormick, J.R., Jensen, E.R., Johnson, S., and Sjolander, N.O. (1968). Biosynthesis of the 
tetracyclines. IX. 4-Aminodedimethylaminoanhydrodemethylchlortetracycline from a mutant of 
Streptomyces aureofaciens. J Am Chem Soc 90, 2201-2202. 
Moyed, H.S., Nguyen, T.T., and Bertrand, K.P. (1983). Multicopy Tn10 tet plasmids confer sensitivity 
to induction of tet gene expression. J Bacteriol 155, 549--556. 
Nguyen, T.N., Phan, Q.G., Duong, L.P., Bertrand, K.P., and Lenski, R.E. (1989). Effects of carriage and 
expression of the Tn10 tetracycline-resistance operon on the fitness of Escherichia coli K12. Mol Biol 
Evol 6, 213--225. 
Price-Whelan, A., Dietrich, L.E., and Newman, D.K. (2006). Rethinking 'secondary' metabolism: 
physiological roles for phenazine antibiotics. Nat Chem Biol 2, 71-78.   21
Sarmah, A.K., Meyer, M.T., and Boxall, A.B. (2006). A global perspective on the use, sales, exposure 
pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. 
Chemosphere 65, 725-759. 
Walsh, C. (2003). Antibiotics : actions, origins, resistance (Washington, D.C.: ASM Press). 
Walton, V.C., Howlett, M.R., and Selzer, G.B. (1970). Anhydrotetracycline and 4-
epianhydrotetracycline in market tetracyclines and aged tetracycline products. J Pharm Sci 59, 1160-
1164. 
Yeh, P., Tschumi, A.I., and Kishony, R. (2006). Functional classification of drugs by properties of their 
pairwise interactions. Nat Genet 38, 489--494. 
Yim, G., Wang, H.H., and Davies, J. (2007). Antibiotics as signalling molecules. Philos Trans R Soc 
Lond B Biol Sci 362, 1195-1200. 
Yuen, P.H., and Sokoloski, T.D. (1977). Kinetics of concomitant degradation of tetracycline to 
epitetracycline, anhydrotetracycline, and epianhydrotetracycline in acid phosphate solution. J Pharm 
Sci 66, 1648--1650. 
 
   22
Chapter 2. 
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Multiple sets of mutations can arise under antibiotic selection, all producing strongly drug-
resistant genotypes. We investigated the genetic interactions that separate adaptive peaks, by 
constructing and characterizing all combinatorial sets of trimethoprim resistance-conferring 
mutations in the DHFR gene, drawn from the results of parallel evolution experiments. The 
resulting adaptive landscape is almost maximally rugged, with direct and indirect 
evolutionary trajectories leading to multiple distinct peaks. Pairwise interactions could not 
explain the existence of multiple peaks, but rather, high-order genetic interactions were   23
responsible for a rugged and multi-peaked adaptive landscape. One mutation could 
profoundly influence the course of evolution: its presence or absence strongly altered the 
ruggedness or smoothness of the adaptive landscape. High-order genetic interactions 
constrain but do not confound the evolution of antibiotic resistance: evolution can always 
find a way to a highly drug-resistant genotype. 
   24
Antibiotic resistance can evolve through the sequential accumulation of multiple resistance-
conferring mutations in a single gene (Lozovsky et al., 2009; Toprak et al., 2012; Weinreich et 
al., 2006). These evolutionary pathways have been studied by examining the feasibility of all 
possible genotypic transitions leading from the ancestor to the evolved drug resistant 
genotype. Across different experimental systems, these studies have observed that only a 
limited number of pathways lead to a single adaptive genotype (Lozovsky et al., 2009; 
Weinreich et al., 2006). However, since these studies examined sets of mutations drawn from 
a single adaptive genotype, it is known a priori that it is ultimately beneficial to acquire all 
mutations, even though the sequence of acquisition may be constrained. However, in a recent 
laboratory evolution experiment where five isogenic, drug-sensitive Escherichia coli 
populations were evolved in parallel under dynamically sustained trimethoprim selection, 
multiple distinct genotypes that shared similar drug resistant phenotypes were observed 
(Toprak et al., 2012). Across all replicate experiments a total of six types of mutations were 
observed  in the dihydrofolate reductase (DHFR) gene (five amino acids were mutated and 
the DHFR promoter was mutated), but each evolving population accumulated a total of four 
of these mutations. Furthermore, the evolutionary trajectories had significant similarities: of 
five drug-adapted cultures, there were two pairs of genotypes that contained the same set of 
mutated residues. This observation suggests that some combinations of mutations were 
superior to others, and yet the different final adaptive genotypes reached remarkably similar 
levels of trimethoprim resistance. We sought to understand the nature of the genotypic 
landscape that produces multiple adaptive genotypes sharing a common drug-resistant 
phenotype.  25
To map genotype to phenotype, we constructed and characterized all combinatorial sets of 
the six types of trimethoprim resistance-conferring mutations previously observed in DHFR 
(Toprak et al., 2012). We studied the effects of one promoter mutation (-35C>T, position 
indicated relative to the transcription start site) and five mutated amino acids; one site had 
been observed to have two different amino acid changes in different adaptive genotypes, 
making for six mutations in total: P21L, A26T, L28R, W30G, W30R, and I94L (Figure 2.1a). 
All combinations amounted to 96 possible variants of DHFR (25×31), which were synthesized 
and recombined into the E.coli chomosome in place of the wildtype DHFR gene (Methods) 
(Bershtein et al., 2012; Datsenko and Wanner, 2000). We were unable to generate 6 mutant 
strains out of 96 despite repeated attempts; we hypothesize that these particular combinations 
of mutations in an essential gene may be unviable (Supplementary Figure 2.1). The 
trimethoprim resistance of the mutant strains was quantified by measuring all strains’ growth 
rates across a gradient of trimethoprim concentrations (Figure 2.1b and Supplementary 
Figure 2.1). Each mutant strain was characterized by two parameters derived from these 
measurements: r0 is the growth rate in the absence of drug, and IC50 is the trimethoprim 
concentration that inhibits growth to 50% of the uninhibited wildtype growth rate (r0
WT/2) 
(Figure 2.1c). From this network of genotypes and their associated growth rates in 
trimethoprim we assembled the adaptive landscape of trimethoprim resistance (Figure 2.1d). 
Amongst each set of genotypes with the same overall number of mutations, a wide 
distribution in trimethoprim resistance was observed. Although each mutation conferred 
significantly increased trimethoprim resistance when acquired on a wildtype background, 
many combinations of two to five mutations generated approximately wildtype susceptibility   26
to trimethoprim. This indicates the presence of strong genetic interactions, in particular 'sign 
epistasis', where a mutation that is beneficial when it arises on one genetic background is 
deleterious when acquired on a different genetic background. 
   27
 
Figure 2.1. Synthetic construction and phenotyping of all combinations of seven 
trimethoprim resistance mutations. a, Trimethoprim resistance can be conferred by any of 
seven different mutations in the target of trimethoprim, DHFR. Each combination of these 
mutations was synthesized and recombined into the E.coli DHFR gene. b, The growth rate of 
each mutant strain was measured in liquid cultures spanning a range of trimethoprim (TMP) 
concentrations. Growth rate is the slope of a linear fit to log(OD600) over time (gray lines). c, 
Fitness costs of mutations are measured by the growth rate in the absence of trimethoprim 
(r0). The trimethoprim concentration that inhibits growth to 50% of the wildtype growth rate 
(IC50) is the intersection of the inhibition curve with the horizontal line where growth 
rate = r0
WT / 2. The growth rates marked by squares (no drug) and triangles (11 μg/mL TMP) 
are derived from the growing cultures shown in Figure 2.1b. d, Mutant strains are distributed 
in rows sorted by number of mutations. Each mutant's genotype is represented by colored 
circles atop a column (see colors in Figure 2.1a) whose height is proportional to the 
trimethoprim resistance (IC50) of that genotype. Each gain of mutation throughout the 
network of genotypes is shown as a line colored by the mutation gained; the series of thick 
lines starting at wildtype are adaptive trajectories observed in a long-term evolution 
experiment (Toprak et al., 2012). The trimethoprim resistance of the wildtype strain and each 
single mutant is shown in a vertically enlarged box for contrast.   28
 
 
 
Figure 2.1. Synthetic construction and phenotyping of all combinations of seven 
trimethoprim resistance mutations. (Continued)   29
We investigated the prevalence of fitness costs in the evolution of trimethoprim resistance by 
determining the correlation between growth rates in the absence of drug (r0) and either the 
number of mutations, or the level of trimethoprim resistance (IC50) (Figure 2.2).  While the 
fitness r0 declined with an increasing number of mutations (r = −0.41, P<10−4), there was no 
correlation between fitness and IC50 (r = −0.02 against log(IC50), P = 0.8). Indeed, many 
combinations of mutations produced high trimethoprim resistance with no significant fitness 
cost, and some other combinations of mutations were not particularly resistant but did incur 
large costs to fitness. Thus, while drug resistance mutations may compromise native protein 
function and incur fitness costs, such fitness costs are not an inevitable consequence of drug 
resistance, because selected combinations of mutations can ameliorate one another's 
deleterious effects and compensate for fitness costs. These observations in E.coli are 
consistent with a previous study of the evolution of pyrimethamine resistance through 
multiple mutations in the dihydrofolate reductase gene of Plasmodium falciparum (Brown et 
al., 2010). 
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Figure 2.2. Though the accumulation of resistance mutations on average incurs fitness 
costs, genotypes exist with high resistance and no cost. a, Fitness costs of mutations are 
assessed by the growth rate in the absence of trimethoprim, and are seen to gradually accrue 
with increasing numbers of mutations. Each point is a genotype positioned by its number of 
mutations and drug-free growth rate; points are color coded green to blue by the number of 
mutations, and a small horizontal scatter is added to improve the visibility of overlapping 
data. b, Each point is a genotype positioned by its trimethoprim resistance (IC50) and drug-
free growth rate (no added scatter), color coded by the same scheme as Figure 2.2a. Because 
of the existence of highly resistant genotypes with no fitness cost, and also weakly resistant 
genotypes with significant fitness costs, IC50 does not correlate negatively or positively with 
growth rate in the absence of trimethoprim.   31
 
 
 
 
Figure 2.2. Though the accumulation of resistance mutations on average incurs fitness 
costs, genotypes exist with high resistance and no cost. (Continued)   32
We examined how evolving populations might move through this landscape by evaluating all 
possible adaptive trajectories. We find 423 possible trajectories along which new mutations 
may be gained, previously acquired mutations may be lost, or an existing mutation can 
convert to a different (non-ancestral) mutation at the same locus; this latter option is possible 
at W30 where two different drug resistance alleles were observed in evolutionary experiments 
(Toprak et al., 2012). Every step in these 423 trajectories continuously improves IC50; neither 
drift nor transient decreases in resistance are permitted, and so they terminate at locally 
adaptive peaks. Examining the mutations that are acquired, and possibly lost, along these 
trajectories, we find that only the promoter mutation (−35C>T) is always acquired, and all 
but one of the amino acid changing mutations has some probability of being acquired and 
subsequently lost or converted in the process of adaption to trimethoprim (Figure 2.3a). 
These instances of mutational reversions must arise from sign epistasis, and demonstrate that 
strong negative genetic interactions produce a landscape on which both direct and indirect 
paths can be taken to adaptive peaks. These observations are supported by the observation of 
indirect adaptive trajectories in the experimental evolution studies that identified this set of 
mutations (Toprak et al., 2012), and are consistent with the fitness landscape of the TEM-1 
β-lactamase which also produces indirect adaptive trajectories (DePristo et al., 2007). 
 
It is unclear whether evolutionary trajectories in a rugged, multi-peaked adaptive landscape 
are guaranteed to find a path to a highly adaptive peak, or whether evolution might be 
trapped at local optima (Poelwijk et al., 2007). The rugged and multi-peaked landscape of 
trimethoprim resistance through mutations in DHFR allows us to address this question. For   33
each genotype we asked what is the most advantageous step (best change in IC50) accessible 
from that genotype? Genotypes have neighbours that are accessible by gaining, losing, or 
converting a mutation; for example, a genotype with four mutations (Figure 2.3b, pillar at 
center) can make seven possible genetic changes, including two gains of mutation, four losses 
of mutation, and possibly a conversion of a mutation. In the example in Figure 2.3b, only two 
changes can improve trimethoprim resistance: either loss of P21L or conversion of W30G to 
W30R, with the latter being the most advantageous step. The best possible improvement in 
IC50 from each genotype is plotted as a function of that genotype's initial IC50 (Figure 2.3c, 
black points), and when the best step is not to gain a mutation, we also show what the best 
step would be if only the gain of mutations was permitted (Figure 2.3c, orange points show 
best possible gain when this is an inferior option to a loss or conversion). We found that the 
best possible steps starting from low resistance were very large, and with increasing levels of 
initial resistance, the best possible steps became smaller in proportion to the reduced 
difference between the initial IC50 and the largest observed IC50. Any genotype where the 
best possible step is negative is a local optima within this set of mutations, since no further 
change in genotype can improve resistance - it is these points that may reveal the existence of 
'evolutionary dead-ends'. This landscape contained seven adaptive peaks, all carrying 4 
mutations, where no further gain, loss or conversion of mutations could improve resistance 
(Figure 2.3c, blue points). These genotypes can be thought of as three truly distinct peaks: two 
genotypes that are not neighbours of any other peaks (Figure 2.3d, two genotypes to far 
right), and a set of five genotypes that are connected by almost neutral drift through two 
other genotypes that carry 5 mutations (Figure 2.3d, connected set of genotypes). At many   34
genotypes the best possible gain of a new mutation confers less improvement in resistance 
than is possible by loss or conversion of a previously held mutation. In particular, many of 
these genotypes would be a local optimum if there were not advantageous steps out of these 
states through the loss or conversion of mutations. Thus, this adaptive landscape would be 
difficult to navigate by only gaining mutations: evolutionary trajectories could be trapped by 
many local optima, but these evolutionary 'dead-ends' are escaped by beneficial losses or 
conversions of mutations. Strong genetic interactions are thus the antidote to their own 
poison: sign epistasis can give rise to genotypes where the further gain of usually beneficial 
mutations is instead deleterious, but sign epistasis also acts upon previously acquired and 
previously beneficial mutations to make their loss or conversion a beneficial step facilitating 
continued adaptation. 
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Figure 2.3. Conversion and reversions bypass evolutionary dead ends, guaranteeing a path 
to reach one of several highly adaptive peaks. a, Simulated evolutionary trajectories over the 
adaptive landscape of DHFR (Figure 2.1d) show that when evolving trimethoprim resistance, 
it can be advantageous to lose a previously acquired 'resistance' mutation. b, Genotypes can 
change by the gain, loss, or conversion of mutations. Starting from the genotype encircled in 
black, the best possible improvement in IC50 is shown as a black arrow. Alternatively, one 
can evaluate the accessibility of the landscape if only the gain of new mutations is permitted; 
the best gain of mutation is shown as an orange arrow, which in this example lowers 
resistance. c, Determining the best possible improvement in IC50 shows that significant steps 
towards the maximum trimethoprim resistance are possible from all genotypes, provided that 
gain, loss, or conversion of mutations are permitted (black points). For genotypes where the 
best step is a loss or conversion of a mutation, the inferior option presented by only gaining 
new mutations is shown in orange. Orange points within the gray zone (below '×1' change in 
IC50) would be local optima, where an evolving population could be trapped at intermediate 
trimethoprim resistance, if it were not for escape by the loss or conversion of mutations. True 
peaks (blue points) are genotypes where no further gain, loss, or conversion of mutations can 
improve IC50. d, Seven genotypes each with 4 mutations are adaptive peaks. Five of these can 
be conceived of as a single 'adaptive plateau' (genotypes on left side) since they are connected 
through almost neutral transitions to two genotypes with 5 mutations (colored lines indicate 
the mutations gained or lost in these transitions). No pair of mutated sites is intrinsically 
incompatible - every possible pair co-exists in an adaptive peak.   36
 
 
 
 
Figure 2.3. Conversion and reversions bypass evolutionary dead ends, guaranteeing a path 
to reach one of several highly adaptive peaks. (Continued)    37
We next investigated the genetic interactions that produce distinct adaptive peaks. It can be 
proven mathematically that an adaptive landscape can only contain multiple peaks in the 
presence of peak-separating 'reciprocal sign epistasis', where two mutations (e.g. A → a and 
B → b) each change the sign of their effect when applied together; i.e. the transition AB → aB 
has an opposite effect to Ab → ab, and AB → Ab also has an opposite effect to aB → ab. This 
scenario is necessary to create losses of fitness along all genetic paths between two adaptive 
peaks, without which there would only be a single adaptive peak (Poelwijk et al., 2011). The 
separation of adaptive peaks by reciprocal sign epistasis has been previous observed as arising 
from pairwise incompatibility between two mutations; i.e. mutations a and b are individually 
beneficial, but deleterious when applied in combination. This interaction creates two separate 
evolutionary lineages, one with a and one with b, leading to separate adaptive peaks (Kvitek 
and Sherlock, 2011; Salverda et al., 2011). However, simple pairwise incompatibility cannot 
explain the multiple adaptive peaks observed in this landscape, because each possible pair of 
mutations is found to co-occur in an adaptive peak (Figure 2.3c). Since there are no 
intrinsically incompatible pairs of mutations, the genetic interactions that separate adaptive 
peaks must be more complex in nature. 
 
Inspecting the genetic interactions between pairs of mutations revealed high-order genetic 
interactions where a given pair of mutations could display a variety of qualitatively different 
interactions with each other, depending upon the presence of yet other mutations (Figure 
2.4a). 'Ruggedness' is the propensity for genetic interactions to change the sign of a mutation's   38
phenotypic effect (from advantageous to deleterious or vice versa); to understand the 
ruggedness of this adaptive landscape we investigated higher-order interactions by 
quantifying how each mutation affects the interactions amongst all other mutations. We 
defined a metric for ruggedness where each mutation i is assigned an information entropy Hi, 
calculated from the probability that acquiring the mutation has a beneficial (p+) or deleterious 
(p−) effect, over all possible genotypes on which it could be acquired: Hi = −p+.ln(p+) 
−p−.ln(p−). The overall ruggedness is the sum of each mutation's information entropy (∑i Hi). 
When the IC50s of two neighboring genotypes are within experimental error (Methods), we 
regard this as a neutral transition that does not contribute to the calculation of ruggedness. 
This definition permits that even if some mutations are beneficial and some are deleterious, 
the ruggedness is 0 provided each mutation is always beneficial or neutral, or always 
deleterious or neutral. Ruggedness is maximized when every mutation has equal chance of 
being beneficial or deleterious. Strikingly, by this metric the adaptive landscape as a whole 
(Figure 2.1d) is 83% as rugged as the theoretical maximum. For each mutation, ruggedness 
was calculated for the subset of the adaptive landscape lacking that mutation, and over the 
subset of the landscape always possessing that mutation (Figure 2.4b). For four mutations 
(−35C>T, A26T, W30R, I94L) their presence or absence had no effect on ruggedness, two 
mutations (L28R, W30G) modestly increased ruggedness when present, and one mutation, 
P21L, was the largest contributor: its presence nearly doubled ruggedness (49% vs. 90% of the 
theoretical maximum). Importantly, P21L is not simply incompatible with other mutations; 
P21L exists together with every other type of mutation in adaptive peaks, whose resistance 
would (by definition) decrease if P21L reverted to wildtype (Figure 2.3d). Rather, the presence   39
of P21L dramatically increases the likelihood that acquiring other commonly beneficial 
mutations will instead be deleterious (Figure 2.4b). We viewed the relation between IC50 and 
number of mutations, with or without P21L, to investigate how this ruggedness-inducing 
mutation affects the evolutionary process. Without P21L the maximum possible resistance 
increases rapidly at first before reaching a peak at certain combinations of 4 mutations, and 
including all 5 mutations besides P21L is approximately equal in resistance to the peak 
(Figure 2.4c, Figure 2.3d). This 'diminishing returns' epistasis is consistent with other studies 
of interactions between advantageous mutations, and may be a general property of adaptive 
evolution (Chou et al., 2011; Khan et al., 2011). However, in the presence of P21L the 
continued accrual of 'trimethoprim-resistance' mutations generates worse than diminishing 
returns: after resistance reaches a maximum at a combination of 4 mutations, the resistance 
of any set of 5 or 6 mutations is lower (Figure 2.4c). Similarly, many combinations of 3 to 5 
mutations that include P21L produce lower trimethoprim resistance than is found with any 
single mutation. 
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Figure 2.4. Ruggedness is the result of high-order genetic interactions, which are strongly 
induced by one mutation. a, P21L (red) and W30R (green) possess widely varying genetic 
interactions with one another when acquired on different genetic backgrounds. Mutations are 
indicated by colored dots and column height represents trimethoprim resistance (IC50). Red 
and green arrows point in the favorable direction for gaining or losing the P21L or W30R 
mutations, respectively. b, Ruggedness is calculated from the information entropy of 
mutations' effects: zero when each mutation's effect has a consistent sign, and maximised 
when each mutation has equal chance of being beneficial or deleterious. Calculating 
ruggedness from subsets of the adaptive landscape that excluding or including each mutation 
reveals that P21L is most responsible for ruggedness; when absent, other mutations are rarely 
deleterious, but when present, beneficial or deleterious effects are equally probable (pie charts 
over P21L). In contrast the presence or absence of I94L, for example, does not substantially 
alter the probability that other mutations are beneficial or deleterious (pie charts over I94L). 
c, Without P21L, trimethoprim resistance evolves with diminishing returns: fold-increases in 
IC50 become progressively smaller, until the addition of further 'resistance' mutations makes 
no significant change to resistance. Adaptation in the presence of P21L is much more rugged: 
acquiring fifth or sixth 'resistance' mutations lowers resistance from the peak, and many 
genotypes of 3 to 5 mutations are almost equally or even more susceptible to trimethoprim 
than wildtype. Solid red and black lines show the maximum level of trimethoprim resistance 
obtained with a given number of mutations (with or without P21L respectively). Points are 
shown with a small horizontal scatter to improve the visibility of overlapping data.   41
 
 
 
Figure 2.4. Ruggedness is the result of high-order genetic interactions, which are strongly 
induced by one mutation. (Continued)    42
The evolution of trimethoprim resistance through mutations in the drug's target DHFR is 
characterized by erratic genetic interactions. Adaptive pathways can take indirect paths, 
gaining, losing, or converting mutations along the way to any of several adaptive peaks. These 
multiple adaptive peaks are separated not by consistent pairwise incompatibilities between 
mutations, but by high-order genetic interactions where the genetic interaction between a 
pair of mutations widely varies depending on other mutations in the background genotype. 
One mutation has the ability to induce a level of ruggedness that is close to the theoretical 
maximum, giving rise to 'worse than diminishing' returns that prevent the continued gain of 
otherwise advantageous mutations. Despite these effects, indirect mutational paths can 
circumvent dips in fitness and thereby guarantee evolving populations a path to a highly 
drug-resistant genotype. 
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Methods 
 
Strains and media 
All DHFR mutant strains were constructed in MG1655 attTn7::pRNA1-tdCherry (gift from 
N.D. Lord). Growth rate measurements were performed in M9 minimal medium (6 g.L–1 
Na2HPO4, 3 g.L–1 KH2PO4, 1 g.L–1 NH4Cl, 0.5 g.L–1 NaCl, 3 mg.L–1 CaCl2) supplemented with 
0.4% glucose, 0.2% casamino acids, and 1mM MgSO4. D r u g  s o l u t i o n s  w e r e  m a d e  f r o m  
powder stock (Sigma Aldrich: chloramphenicol, C0378; kanamycin, K1876; trimethoprim, 
T7883). 
 
Chromosomal Integration 
Mutant DHFR strains were constructed by replacing the endogenous (coding and noncoding 
regions) of the DHFR gene with chemically synthesized mutant DHFR sequences, following 
the method of (Datsenko and Wanner, 2000) specifically adapted for DHFR (Bershtein et al., 
2012). Briefly, mutant DHFR genes, including the native DHFR promoter, were synthesized 
and cloned into a plasmid with flanking kanamycin and chloramphenicol resistance genes. 
The integration cassette was PCR-amplified with primers possessing 60 nucleotide homology 
to the genes immediately upstream (kefC) and downstream (apaH) of DHFR in the E.coli 
chromosome. PCR products were DpnI digested (New England Biolabs, R0176) and   45
electroporated into strains carrying the lambda Red recombinase expression plasmid pKD46 
(Datsenko and Wanner, 2000). Integrants were selected on Lysogeny Broth (LB) agar with 30 
mg.L–1 kanamycin and 25 mg.L–1 chloramphenicol. Colony purification at 42°C removed the 
pKD46 plasmid, which was confirmed by a failure to grow on LB agar with 100 mg.L–1 
ampicillin. Single colonies were Sanger sequenced to verify the sequence of the mutated 
DHFR locus. Mutated DHFR genes were transduced by phage P1 into naive MG1655 
attTn7::pRNA1-tdCherry, transductants were selected on LB agar with kanamycin and 
chlorampenicol, and single transductant colonies were sequenced to again confirm the 
mutated DHFR sequence. Gene synthesis services were provided by GenScript, and DNA 
sequencing services were provided by GENEWIZ. 
 
Phenotyping assay 
Frozen stocks of all mutant strains were prepared in one master 96-well plate (LB with 15% 
glycerol). Approximately 0.3μL of each frozen stock was transferred by a pin replicator (V&P 
Scientific, VP408) to the corresponding wells of a range of 96-well plates, with 150μL of M9 
minimal media per well. Each of these plates possessed one trimethoprim concentration out 
of a 23-point range from 0.2 to 3000 μg.mL–1, plus duplicate cultures with no trimethoprim. 
Plates were incubated with shaking at 30°C and 70% humidity in an environmental room, 
and each well’s optical density at 600nm (OD600) was measured every 60 minutes. To more 
precisely measure growth rate in the absence of drug, the assay was repeated with fewer plates 
(duplicate cultures with no trimethoprim) and more frequent measurements (every 15   46
minutes); additionally growth was measured at 3600 μg.mL–1 trimethoprim to verify that this 
concentration inhibited the growth of all mutant strains. 
 
Growth rate and IC50 determination 
A background optical density of 0.03 units was subtracted from each OD600 measurement, 
based upon the optical density of a control empty well present in all assays. Along the 
experimentally measured functions of log(OD600) over time, linear fits were made to each 
series of four data points (four hours of growth). A time series of growth rates was 
constructed from the slopes of these linear fits, which was then smoothed by a median filter 
(median of 3 consecutive growth rates). The most rapid growth rate of this median-smoothed 
series was taken as the growth rate of that culture at that trimethoprim concentration. For the 
more frequently measured cultures with no trimethoprim, the same protocol was applied 
except that linear fits were made to every 7 consecutive log(OD600) measurements, and the 
median filter was taken over 5 consecutive growth rates. 
 
The trimethoprim resistance of each strain was quantified by the IC50, as calculated from the 
function of growth rate versis trimethoprim concentrations. Specifically, linear interpolations 
of growth vs log([trimethoprim]) were constructed, and IC50 was calculated as the largest 
trimethoprim concentration at which this linear interpolation of growth rate was equal to half 
of the uninhibited wildtype growth rate (half of 0.7 doublings/hour = 0.35 doublings/hour).   47
To quantify the experimental error in IC50 measurements, a distribution of IC50 estimates 
was acquired by performing the above protocol on an ensemble of 1000 functions of growth 
rate versus trimethoprim, where for every member of the ensemble each growth rate 
measurement is multiplied by a number drawn from a normal distribution with a mean of 1 
and a standard deviation of 0.07; chosen such that the artificially 'noisy' data set has a Z-score 
that is twice the Z-score of the duplicate experimental measurements with no trimethoprim. 
From this ensemble, a standard deviation was calculated for each genotype's IC50; this 
standard deviation was small when growth is inhibited over a narrow range of trimethoprim 
concentrations, and large when growth gradually declines over a wide range of trimethoprim 
concentrations. When simulating evolutionary trajectories (Figure 2.3a) and calculating 
landscape ruggedness (Figure 2.4b), we required 99% confidence that the IC50 values of 
neighboring genotypes were not equal, or else they were considered to be connected by 
neutral drift. Drift transitions between genotypes were not permitted in simulated 
evolutionary trajectories, and drift transitions did not contribute to the calculation of 
ruggedness, where information entropy was calculated only from confidently beneficial or 
confidently deleterious transitions.   48
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The effects of antibiotics are mediated by their direct or indirect interactions with individual 
proteins in the cell, as well as by the abundance of those proteins. Hence, antibiotic resistance 
can evolve not only by mutations that change the amino acid sequences of proteins, but also 
by mutations that change the expression level of proteins. To explore the potential of changes 
in gene expression to confer antibiotic resistance, we implemented a pooled diffusion-based 
assay to screen all viable gene over-expression and gene deletion mutants of Escherichia coli 
against a broadly representative panel of 31 antibiotics. We found 136 positive or negative 
changes in gene expression that confer drug-specific or multi-drug resistance. These genes 
span a diverse range of functions and most were not previously associated with antibiotic 
resistance; only 4 are drug targets. By quantitatively adjusting gene expression and measuring 
resistance, we find that intrinsic antibiotic defense systems, and also 'protoresistance' genes 
that hold enormous potential for resistance, are often regulated so as to actually confer little 
resistance to the wildtype strain. We rationalize the abundance and diversity of hits by   51
viewing gene-regulation as an optimization problem: because antibiotic treatment results in 
the non-optimal expression of some genes, there exist many possibilities for the evolution of 
drug resistance through regulatory mutations that deploy latent defense capabilities or correct 
other errors in gene expression.   52
Mutations can confer antibiotic resistance by changing the amino acid sequence of a protein 
(coding mutations) or by altering the expression level of proteins in a cell (non-coding, 
regulatory mutations). Resistance mutations have been identified in regulatory sequences in 
antibiotic resistant isolates from the clinic and from laboratory evolution experiments. These 
mutations have been found to confer antibiotic resistance by mechanisms such as over-
expression of a drug’s target, over-expression of drug defense systems, and the down-
regulation or deletion of genes required for drug entry or enzymatic activation of a pro-drug. 
Examples include: trimethoprim resistance acquired by over-expression of its target enzyme 
dihydrofolate reductase (Flensburg and Skold, 1987); penicillin resistance acquired by the 
over-expression of drug degrading beta-lactamases (Bergstrom and Normark, 1979); and 
cephalosporin resistance acquired  by loss of porins through which the drug enters the cell 
(Curtis et al., 1985). However, these and other examples have generally been identified 
individually, and because regulatory mutations can act in trans it remains challenging to 
systematically identify regulatory pathways to drug resistance by genotypic approaches 
(Courvalin, 2005). This limitation can be overcome through the use of genome-wide libraries 
of strains where each has a defined change in gene expression, e.g. deletion or over-
expression. Genome-wide screens with such libraries have identified gene deletions which 
confer antibiotic hypersensitivity (Girgis et al., 2009; Tamae et al., 2008), and gene 
duplications which confer stress resistance; although the latter study utilized a competitive 
growth method that only identified 1 to 3 genes per stress (Soo et al., 2011). The most 
comprehensive such studies screened all viable homozygous and heterozygous gene deletions 
in diploid S. cerevisiae or all viable gene deletions in E. coli against hundreds of chemical   53
stresses (Hillenmeyer et al., 2008; Nichols et al., 2011). However, as both of these studies 
aimed to measure phenotypic signatures for each gene, stresses were applied only at sub-
inhibitory levels, and so gene deletions that confer survival at normally lethal stress levels 
were not identified. Thus, a systematic and sensitive screen for positive and negative changes 
in gene expression that confer antibiotic resistance is absent. 
 
In this study, we perform functional genetic screens in E. coli for drug-specific and multi-
drug resistance conferred by increasing or decreasing gene expression levels, using a panel of 
antibiotics representing most classes effective against gram-negative bacteria. To accomplish 
this, we developed a robust genome-wide screen to identify gene expression changes 
conferring drug resistance. We employ two E.coli strain libraries: the 'KEIO' collection of 
strains containing each viable gene deletion (Baba et al., 2006), and the 'ASKA' collection 
wherein each gene is individually expressed from an IPTG-inducible promoter on a plasmid 
(Kitagawa et al., 2005). The ASKA collection of plasmids was transformed from its host 
cloning strain to the 'wildtype' MG1655 ΔlacIZYA for healthy growth; additionally the 
lacIZYA deletion allows IPTG to exclusively induce plasmid-based expression without fitness 
effects from induction of the lac operon. Screening large strain collections for drug-resistant 
mutants typically requires exploring a range of discrete, finely-tuned drug concentrations 
using high-throughput laboratory automation. We have addressed these challenges with a 
simple two-step pooled diffusion-based screen on agar (Figure 3.1a): (1) a strain library 
(deletion or over-expression) is pooled and seeded as a lawn on agar. An aliquot of 
concentrated drug solution is spotted in the center of the plate, as in a classical disc-diffusion   54
assay, and diffuses through the media to form a continuous spatial gradient of drug 
concentrations. Typically, following incubation, the wild type strain will grow into a dense 
lawn across the plate, except in a zone of clearing surrounding the drug source, where drug 
concentrations are high enough to preclude growth. Strains with enhanced resistance to the 
drug can grow in the higher drug concentrations closer to the center, and are thus visible as 
individual colonies inside the zone of inhibition; (2) Drug resistant colonies are picked and 
identified by Sanger sequencing of the expression plasmid or of the chromosome adjacent to 
the site of a gene deletion (Supplementary Methods).  Because the diffusion gradient samples 
a continuum of drug concentration space, this rapid and inexpensive assay is robust with 
respect to drug concentrations and sensitively detects improvements in drug resistance.  
 
We employed our assay on 31 antibiotics, representing all major classes of antibiotics effective 
against gram-negative bacteria (Table 3.1). The gene deletion collection represents the 
extreme case of down-regulation, and utilizing the IPTG-inducible promoter driving the gene 
over-expression collection, we screened against both weak and strong up-regulation (using 
15μM and 150μM IPTG, respectively). 48 colonies were picked and sequenced for each of 
three expression conditions per drug (deletion, weak over-expression, strong over-
expression). Inspection of the assay plates reveals discrete colonies within the high drug 
concentration zones of clearing, showing that both gene deletion and gene over-expression 
can confer drug resistance. The presence and abundance of drug-resistant gene expression 
mutants is highly variable across drugs, with very strongly resistant mutants appearing on 
some drugs (e.g. penicillin G, trimethoprim) while some drugs permitted no resistant   55
mutants (e.g. colistin) (Figure 3.1b). In contrast, the ‘wildtype’ reference plates rarely show 
colonies in the zone of inhibition, representing infrequent spontaneous drug resistance 
mutations. To avoid false identifications from the occurrence of spontaneous resistance 
mutations, we required two or more observations of each specific gene-drug interaction (false 
discovery rate ≤ 1%). We also noted a few interactions where a change in gene expression that 
had been repeatedly observed to resist one drug (satisfying the previous criteria) was also 
observed once with a second drug of the same mode of action (false discovery rate ≤ 5%). 
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Table 3.1. List of antibiotics used in this study, mechanism of action, and abbreviation. 
 
Mechanism 
of action 
Drug class  Drug name  Abbr. 
Cell Wall 
Synthesis 
Cephalosporin 
Cephalexin CLX 
Cefoxitin FOX 
Cefsulodin CFS 
Glycopeptide Vancomycin  VAN 
Penicillin 
Ampicillin AMP 
Carbenicillin CRB 
Mecillinam MEC 
Penicillin G  PEN 
Cell Membrane 
Polypeptide 
Colistin COL 
Polymyxin B  PMB 
Fatty acid synthesis inhibitor  Triclosan  TCL 
Transcription Rifamycin  Rifamycin  SV  RIF 
Translation 
 
Aminoglycoside 
Amikacin AMK 
Streptomycin STR 
Tobramycin TOB 
Macrolide 
Azithromycin AZI 
Erythromycin ERY 
Spectinomycin SPX 
Spiramycin SPR 
Lincosamide Clindamycin  CLI 
Tetracycline 
Doxycycline DOX 
Tetracycline TET 
DNA Synthesis 
Quinolone 
Ciprofloxacin CPR 
Lomefloxacin LOM 
Nalidixic acid  NAL 
Folate synthesis inhibitor 
Trimethoprim TMP 
Sulfacetamide   SCM 
Sulfamethoxazole SMX 
Free radical 
production 
Glycopeptide 
Bleomycin BLM 
Phleomycin PHM 
Nitrofuran Nitrofurantoin  NIT 
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Figure 3.1. A genome-wide screen identifies changes in gene expression that confer 
antibiotic resistance. a, A library of  E.coli strains with genes deleted or overexpressed is 
pooled and plated as a lawn on agar.  A drug spot is applied which creates a zone of growth 
inhibition. Members of the strain library with increased drug resistance grow inside the zone 
of inhibition (yellow colonies), and are picked and identified by DNA sequencing. b, 
Photographs of assay plates for five example drugs (out of 31 drugs in total) illustrate that 
both gene deletion and over-expression can confer drug resistance, and the possible levels of 
resistance range from none at all (e.g. colistin), to modest (e.g. clindamycin, vancomycin), to 
very strong (e.g. penicillin, trimethoprim). Plate images of all drugs are shown in 
Supplementary Figure 3.1.   58
 
 
Figure 3.1. A genome-wide screen identifies changes in gene expression that confer 
antibiotic resistance. (Continued)   59
We sequenced over 2400 drug resistant colonies and identified over 200 gene-drug 
interactions where a change in gene expression was repeatedly observed to increase resistance 
to an antibiotic. These changes in gene expression consisted of a mixture of over-expression 
and deletion (59% and 41% of genes, respectively) (Figure 3.2). For only 4 of 31 drugs did we 
not identify any changes in individual gene expression that confer resistance, and 2 of these 
were the membrane-disrupting drugs colistin and polymyxin B where it is unclear how an 
internal change in gene expression might improve resistance. The majority of expression 
changes were observed to increase resistance to drugs only within a single mechanistic class 
(93% of genes), and have not been previously associated with drug resistance (83% of genes). 
Amongst those genes known to be associated with antibiotic resistance, we have reproduced 
several drug-specific and multi-drug resistant regulatory mutations previously identified in 
clinical isolates or experiments (Supplementary Table 3.1). These results demonstrate that for 
most antibiotics there are many regulatory mutations with the potential to increase resistance.    60
 
 
 
 
 
Figure 3.2. Many positive and negative changes in gene expression can confer drug 
resistance. Drugs (black hexagons) are grouped by mechanism of action (see Table 3.1 for 
abbreviations). E. coli genes are marked by red circles when deletion confers drug resistance 
and blue circles when over-expression confers drug resistance; known drug targets whose 
over-expression confers resistance are outlined in dark blue. Changes in gene expression that 
resist only one mechanism of drug action are grouped around the drugs of that mechanism, 
while those that resist multiple classes of drug are shown in the center. Pale colored links 
denote changes in gene expression that were identified only once as resisting a particular 
drug, that are included because they were repeatedly observed to resist another drug of the 
same mechanism of action. Supplementary Table 3.1 lists all gene-drug interactions   61
 
 
 
 
Figure 3.2. Many positive and negative changes in gene expression can confer drug 
resistance. (Continued)   62
A multitude of drug-specific pathways to resistance were observed. Amongst those genes with 
annotated functions, a diverse range of possible resistance mechanisms are demonstrated or 
suggested. Resistance mechanisms suggested by functional annotations include modification 
of the cellular process affected by a drug, increased flux through a drug-inhibited pathway, 
modification of cell permeability, chemical modification of a drug, and the activation of drug 
efflux and acid resistance systems (Table 3.2). Additionally, resistance to various antibiotics 
resulted from changes in the expression levels of numerous genes involved in the metabolism 
or transport of lipopolysaccharide, enterobactin, polyamines, and ubiquinone. These cases 
where a resistance mechanism can be inferred, or at least a particular metabolic process is 
implicated, represent only one third of the changes in gene expression that increase antibiotic 
resistance, while the remaining two thirds act by yet unclear mechanisms. 
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Table 3.2. Mechanisms of drug resistance mediated by changes in gene expression. 
See Supplementary Table 3.1 for all gene-drug interactions and functional annotations. 
Genetic change  Putative resistance mechanism 
Modification of a cellular process affected by drug 
sbmC  Inhibits DNA Gyrase and confers resistance to DNA damage by phleomycin
ΔdacA  Alters the peptidoglycan moiety bound by vancomycin
ΔrodZ  Loss of a binding partner of the target of mecillinam confers mecillinam resistance
ΔdksA 
Loss of an RNA Polymerase binding protein increases resistance to the RNA 
Polymerase inhibitor rifamycin SV 
hflX 
Over-expression of ribosome component increases resistance to the translation 
inhibitors clindamycin and erythromycin 
ΔrpmG  Loss of ribosome component increases clindamycin resistance  
Alteration of cell permeability 
ΔompF, ΔompR, ΔasmA  Loss of the porins through which cephalosporins enter the cell 
ΔsbmA  Loss of a transporter through which antimicrobial peptides enter the cell 
amiA  Increased expression of a peptidoglycan amidase 
bssR  Increased expression of a biofilm regulator
Increased flux through drug-inhibited pathway 
nudB  Increased rate of first reaction in folic acid synthesis pathway 
ΔfolM, ΔfolX 
Increased flux through folic acid synthesis pathway by preventing substrate use for 
tetrahydromonapterin synthesis 
folM  Drug-insensitive replacement for a drug-inhibited enzyme 
folA, mrcB, mrdA, fabI  Increased expression of a drug-inhibited enzyme
Drug modification 
ΔnfsA  Loss of enzyme that catalyzes pro-drug activation 
ampC  Expression of enzyme that inactivates drug
Drug resistance / drug efflux systems 
marA, soxS  Transcriptional activation of multidrug resistance systems 
Δlon, ΔrsxC  Loss of enzyme required for inactivation of mar or sox systems, respectively 
ycjR  Component of SdsRQP efflux pump
baeR  Increased transcription of MdtABC efflux pump
Acid resistance systems 
cadA, cadB  Activation of Lysine-dependent acid resistance system
gadE, gadW, ydeO  Activation of Glutamic acid decarboxylase acid resistance system 
Lipopolysaccharide metabolism 
 ΔlpcA, ΔrfaC, ΔrfaD  Defects in lipopolysaccharide synthesis and modification
eptB  Increased phosphoethanolamine modification of lipopolysaccharide 
Enterobactin transport and modification 
ΔfepB, ΔfepC, ΔfepG  Loss of ferric enterobactin ABC transporter
Δfes  Loss of ferric enterobactin hydrolysis
entS  Increased expression of enterobactin transporter
Polyamine metabolism and transport 
puuP  Increased expression of putrescine transporter
rpmH  Decreased polyamine synthesis, but increased intracellular polyamines 
ΔspeA, ΔspeB  Loss of putrescine biosynthesis
Ubiquinone metabolism 
ΔubiF, ΔubiG, ΔubiH  Loss of ubiquinone biosynthesis 
nuoI  Increased expression of NADH:ubiquinone oxidoreductase   64
We also identified 9 genes whose over-expression increases resistance against multiple 
mechanisms of drug action (e.g. both cell wall synthesis drugs and DNA synthesis drugs), 
including the known multi-drug resistance genes marA and soxS, and 7 novel multi-drug 
resistance genes of varied functions. gadW is a transcriptional regulator of acid resistance; 
bssR regulates biofilm formation and may confer multidrug resistance through altered 
permeability; and ddpF is a putative component of an ABC transporter. The functional 
annotations of the remaining 4 multi-drug resistance genes (hemD, yhbT, gmr, and rbsR; see 
Supplementary Table 3.1) do not suggest potential mechanisms of resistance.  
 
Regulatory mutations in the specific targets of drugs are of particular interest. While many 
antibiotics are not inhibitors of a single protein (instead inhibiting a large complex, a family 
of related enzymes, or damaging a non-protein target such as the cell membrane), 10 of the 31 
antibiotics in our screen specifically bind to one or two enzymes. If an antibiotic acts by 
disrupting the activity of its target, a higher concentration of the target might be able to 
restore its activity. Strikingly, only 4 of these 10 antibiotics were resisted by over-expression of 
their target gene, and 2 of these only when over-expressed weakly, not strongly (Figure 3.2, 
Table 3.3). Thus, a drug's direct target can be absent from the set of regulatory mutations that 
confer drug resistance. 
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Table 3.3. Many specific inhibitors are not resisted by over-expression of their target. 
Only 4 antibiotics were resisted by over-expression of their specific target gene(s), and for 2 of 
these resistance was only conferred by weak, but not strong, target over-expression (genes 
with *). Conversely, antibiotic resistance can often be increased by the over-expression of 
certain non-target genes. 
Antibiotic 
Target over-expression 
confers resistance? 
Non-target genes that 
confer resistance when 
over-expressed (#)  Yes No 
Cephalexin    ftsI 12
Cefsulodin  mrcB*  mrcA 3
Mecillinam  mrdA*  11
Trimethoprim  folA  2
Sulfamethoxazole    folP 3
Sulfacetamide    folP 6
Ciprofloxacin    gyrA, parC 4
Lomefloxacin    gyrA, parC 0
Nalidixic acid    gyrA, parC 2
Triclosan  fabI  0
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These gene-drug interactions identify genes for which a change in expression improves 
survival, and therefore are not optimally regulated under antibiotic stress in the wildtype cell. 
For these genes the response of a wildtype cell to antibiotic treatment produces less than, or 
perhaps even none, of its maximal potential for antibiotic resistance that could be achieved 
with an optimal regulatory response. We investigated what fraction of the maximum 
potential resistance is realized by E. coli for the 2 most broadly protective multi-drug 
resistance genes, marA and soxS, and for 2 strong drug-specific resistance genes, ampC and 
sbmC. To answer this question it is necessary to remove the native transcriptional regulation 
mechanisms and obtain full experimental control over these genes’ expression. We achieve 
this by constructing hybrid ‘gene deletion - gene expression’ strains in which a plasmid 
bearing IPTG-regulated gene expression is transformed into a strain where the matching gene 
is deleted from the chromosome (Figure 3.3a). Two-dimensional gradients of drug dose and 
IPTG-controlled gene dose were constructed across microtiter plates and bacterial growth 
rates were measured using a bioluminescence assay with sensitivity far exceeding optical 
density techniques (Kishony and Leibler, 2003). These experiments assessed how drug 
resistance depends on gene expression and how the maximal possible drug resistance 
compares to the resistance of the wildtype strain and a strain lacking the gene. 
 
MarA and SoxS are global regulatory transcription factors with partially overlapping sets of 
target genes whose activation confers resistance to multiple antibiotics, organic solvents, and 
oxidative stresses through mechanisms such as upregulation of efflux pumps and 
downregulation of porins (Alekshun and Levy, 1999; Martin and Rosner, 2002). The growth   67
of strains with regulated expression of either marA or soxS were examined in concentration 
gradients of 9 antibiotics representing the 4 modes of action that were observed to interact 
with marA and soxS. We find that marA and soxS have the potential to boost resistance to 
ampicillin, mecillinam, clindamycin, doxycycline, ciprofloxacin and trimethoprim (Figure 
3.3b). However, this potential for resistance is only well used by the wildtype strain in the case 
of clindamycin (marA and soxS) and trimethoprim (soxS only), and then only under strong 
growth inhibition, and not at moderate growth inhibition. (Figure 3.3c, Supplementary 
Figure 3.3a). Thus, many antibiotics could potentially be resisted by intrinsic stress response 
systems, but remain effective because of a regulatory failure to fully utilize those defenses. 
This phenomenon underlies the clinical observation of mutations that activate the mar or sox 
operons in multi-drug resistant E. coli isolates (Koutsolioutsou et al., 2005; Maneewannakul 
and Levy, 1996). 
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Figure 3.3. Multi-drug resistance systems are often poorly utilized. a, The optimality of a 
gene's response to antibiotic treatment was investigated by comparing the drug susceptibility 
of three E. coli strains: one lacking the gene (black), one with wildtype gene regulation 
(green), and one where susceptibility can be measured over a range of experimentally 
controlled gene expression levels (red). b, The optimality of the responses of the multi-drug 
resistance factors marA and soxS were studied in 9 antibiotics. Drug concentrations are 
normalized by the IC50 (concentration for 50% inhibition) of the strain lacking the gene of 
interest. For regulated gene over-expression, the growth rate shown is the highest over all 
expression levels. For those drugs where gene expression (red) increased resistance relative to 
gene deletion (black), the wildtype strain (green) frequently used only a fraction of the 
potential for drug resistance. c, On an empirical fitness landscape (growth rate vs drug dose 
and gene expression) the gene expression response that maximizes growth at each drug dose 
(red line) can be compared with the wildtype response (green), which is inferred by matching 
the wildtype growth rate to the level of controlled gene expression producing the same 
growth rate. In ampicillin and ciprofloxacin, a sub-optimal use of marA is observed. In 
clindamycin the wildtype cell does not use marA for drug resistance until growth inhibition is 
greater than 50%, after which marA use becomes optimal.   69
 
Figure 3.3. Multi-drug resistance systems are often poorly utilized. (Continued)   70
AmpC is both a beta-lactamase and a peptidoglycan hydrolase required for normal cell 
morphology (Bishop and Weiner, 1993; Henderson et al., 1997). Regulatory mutations that 
increase ampC expression have been observed in clinical and experimental isolates and confer 
strong penicillin and cephalosporin resistance (Bergstrom and Normark, 1979). Under 
treatment by either a penicillin or a cephalosporin, we observe that wildtype ampC expression 
levels provide negligible resistance relative to a ΔampC strain, despite the potential to confer 
100-fold resistance when over-expressed (Figure 3.4a, Supplementary Figure 3.3b). The lack 
of  ampC-mediated resistance in wildtype E. coli s u g g e s t s  t h a t  r a t h e r  t h a n  b e i n g  a  d r u g  
resistance gene, ampC is a 'protoresistance' gene (Morar and Wright, 2010); the primary role 
of ampC is in cell morphology, but it has the capacity to evolve into a beta-lactam resistance 
gene through mutations that increase its expression level. 
 
SbmC is a DNA gyrase inhibitory protein that acts as an antitoxin to DNA gyrase-specific 
protein toxins such as microcin B17, and is induced by the SOS response to DNA damage 
(Baquero et al., 1995; Chatterji and Nagaraja, 2002; Nakanishi et al., 1998; Oh et al., 2001). 
Here we observed that sbmC over-expression confers resistance to phleomycin, a 
glycopeptide that generates free radicals leading to DNA cleavage. Comparing the 
phleomycin susceptibility of ΔsbmC, wildtype, and sbmC over-expressing strains we found 
that, despite the SOS-inducibility of sbmC, only a small fraction of the potential sbmC-
mediated phleomycin resistance was used by a wildtype strain (Figure 3.4b, Supplementary   71
Figure 3.3b). Thus even a specific stress-inducible toxin resistance gene can be inadequately 
utilized against toxins that it can resist.  
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Figure 3.4. Proto-resistance genes hold unrealized potential for strong drug resistance. 
The use of ampC and sbmC under antibiotic treatment was examined by comparing the drug 
resistance of E. coli strains lacking the gene of interest (black), wildtype strains (green), and 
strains with experimentally controlled gene expression that demonstrate the potential for 
drug resistance (red) (see Figure 3.3a). a,  ampC encodes a potent beta-lactamase: over-
expression can confer 100-fold resistance to penicillins or cephalosporins. However, with 
wildtype expression regulation of ampC (green) almost none of this potential resistance (red) 
is used. b, sbmC encodes a DNA gyrase inhibitor whose over-expression confers resistance to 
the DNA-damaging drug phleomycin. However, a wildtype strain (green) treated with 
phleomycin uses very little of the potential resistance offered by sbmC (red).   73
 
 
Figure 3.4. Proto-resistance genes hold unrealized potential for strong drug resistance. 
(Continued)  74
In principle, a mutation can only produce a beneficial effect by changing a gene's expression 
level if that gene's expression was initially sub-optimal, i.e. fitness would be larger at either 
higher or lower expression. Therefore, all non-coding mutations that are beneficial only 
under antibiotic treatment are made possible by a non-optimality in gene expression in the 
presence of the drug. To illustrate this phenomenon, we measured growth rate as a function 
of gene expression for nfsA under nitrofurantoin treatment, and ampC under ampicillin 
treatment. As expected from the previous theoretical arguments, the optimum nfsA 
expression level is lowered by increasing doses of nitrofurantoin, until the expression level 
that is optimal for growth without the drug is lethally sub-optimal in its presence (Figure 3.5). 
In scenarios such as this, mutations that lower or abolish gene expression will confer drug 
resistance. Conversely, the optimum ampC expression level increases with increasing doses of 
ampicillin (Figure 3.5). If actual ampC expression is maintained at the level that optimizes 
growth without drug, the strain will die at drug doses that could have been resisted with 
greater  ampC expression; in this type of scenario, gene over-expression will confer drug 
resistance. These two examples illustrate a universal phenomenon: non-optimal gene 
expression is the pre-condition for a change in gene expression to be beneficial. The simplest 
situation that may give rise to non-optimal gene expression under antibiotic treatment is if a 
gene's expression is optimized for growth in the absence of drug and is not differentially 
regulated in response to drug treatment. There are also examples of more elaborate reasons 
for sub-optimal gene expression: a drug or drug mixture may induce serious physiological 
imbalances between cellular components, outside the usual range of  their global regulation   75
(Bollenbach et al., 2009) or may even induce a harmful regulatory response in drug resistance 
systems (Palmer et al., 2010).   76
 
 
Figure 3.5. Antibiotic treatments can change optimal gene expression levels. The growth 
rate of E. coli was measured as a function of nfsA or ampC expression levels when grown in 
variable doses of nitrofurantoin or ampicillin, respectively; using strains for experimentally 
controlled gene expression as per Figure 3.3a. Nitrofurantoin concentrations were 3μg.mL−1 
(subinhibitory to the wildtype strain) and 4.4μg.mL−1 (inhibitory to the wildtype strain); and 
ampicillin concentrations were 16μg.mL−1 (subinhibitory) and 100μg.mL−1 (inhibitory). Plots 
at top zoom in on growth rates in the absence of drug; gray lines highlight the gene 
expression level that optimizes growth without drug. Nitrofurantoin treatment lowers the 
optimal  nfsA expression level, thus selecting for mutations that lower nfsA expression. 
Ampcillin treatment raises the optimal ampC expression level, thus selecting for mutations 
that elevate ampC expression.   77
Antibiotics inhibit or damage essential processes at micromolar to nanomolar concentrations 
and come in diverse structural forms; the task of detecting and responding to these 
compounds must be a challenge, at which drug-sensitive bacteria succeed partially at best. 
Fitness is an environment-dependent function of gene expression (Dekel and Alon, 2005), 
and antibiotic treatment changes the optimal expression level of many genes that can 
influence drug susceptibility. For each and every such gene, if there is a failure to 
appropriately respond to drug treatment, then regulatory mutations can exist that change 
gene expression, correct this non-optimality, and thereby improve drug resistance. We have 
identified an abundance of functionally diverse pathways to antibiotic resistance by such 
changes in gene expression. While many of these changes have modest drug-specific effects, 
even potent drug resistance genes and multi-drug resistance systems are subject to mutations 
that change gene expression, due to their inadequate or complete lack of usage against many 
antibiotics. Thus, while bacteria can achieve antibiotic resistance by acquiring functional 
mutations and specific resistance mechanisms, we find that they can also draw on an 
unappreciatedly vast pool of mutations that correct gene-regulatory failures and activate 
latent defense mechanisms.    78
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Methods 
Strains and Media 
All selection experiments and growth rate assays were performed in M63 minimal medium 
(2g.L–1 (NH4)2SO4, 13.6g.L–1 KH2PO4, 0.5mg.L–1 FeSO4•7H2O, adjusted to pH 7.0 with KOH) 
supplemented with 0.2% glucose, 0.1% casamino acids, 1mM MgSO4 and 0.5mg.L–1 thiamine. 
 
Escherichia coli strain BW25113 is the host for the KEIO gene deletion library (Baba et al., 
2006; Datsenko and Wanner, 2000). The strains of the KEIO gene deletion library (Baba et al., 
2006) were grown individually in 384-well plates with 80μL of Lysogeny Broth (LB) per well, 
with incubation at 37°C and shaking at 900rpm for 24 hours. All cultures were then collected 
in a single beaker and mixed, passed through 5 micron cellulose acetate filters to disrupt cell 
clumps, and frozen in aliquots at −80°C in 10% glycerol. As the ASKA Open Reading Frame 
(ORF) library of plasmids was supplied in the AG1 cloning strain (Kitagawa et al., 2005), the 
plasmids were purified and transformed in pools into the ‘wildtype’ strain MG1655 rph+ 
ΔlacIZYA (gift from K.E. Shearwin; constructed from BW30270 (CGSC7925) by precise 
deletion of lacIZYA (EcoCyc MG1655: 360527-366797) by recombineering) to minimize 
artifacts arising from the poor health of the cloning strain; additionally the lacIZYA deletion 
allows the use of IPTG to exclusively induce plasmid-based expression without additional 
fitness effects due to induction of the lac operon. No such alterations were required for the 
deletion library as BW25113 has only minor perturbations relative to wildtype MG1655, and 
IPTG was not required to induce a change in gene expression. The AG1 strains of the ASKA   80
library were grown by the same protocol as described for the KEIO library, and the 
chloramphenicol resistance and ORF-encoding pCA24N plasmids were isolated as a pooled 
mixture from each 384-well plate by a QIAGEN Spin Miniprep kit. Plasmid pools were 
transformed into MG1655 rph+ ΔlacIZYA by the one-step protocol of (Chung et al., 1989). To 
enrich for plasmid transformed cells, liquid cultures of transformed E. coli (~109 c.f.u) were 
inoculated into 10mL of M63 minimal medium with 30μg.mL–1 chloramphenicol and were 
incubated overnight at 37°C with shaking at 300rpm. All transformant pools were added to a 
single flask, mixed, and frozen in aliquots at −80°C in 10% glycerol. A wildtype reference for 
the ASKA library was constructed by transforming MG1655 rph+ ΔlacIZYA with a pCA24N 
plasmid encoding yellow fluorescent protein (yfp), but with the promoter deleted (pCA24N-
ΔpT5lac-yfp). 
 
In growth rate assays (Figures 3.3 and 3.4), 'wildtype' refers to BW25113, 'gene deletion' refers 
to the member of the KEIO deletion library lacking the gene of interest (BW25113 -
gene::KanR), where the Kanamycin resistance cassette was been excised by FLP recombinase 
from a temperature-sensitive helper plasmid, yielding a strain BW25113 gene::FRT (Datsenko 
and Wanner, 2000). Excision of kanamycin resistance and loss of the helper plasmid, by 
colony purification at 43°C, was verified by testing for loss of antibiotic resistances. 
Controlled gene expression was produced by complementing a gene deletion strain with a 
pCA24N plasmid with isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible expression 
of the deleted gene; these plasmids were obtained from the ASKA library and the Open   81
Reading Frames were sequenced to confirm gene identity (Kitagawa et al., 2005). As lacIZYA 
is deleted in BW25113, IPTG does not incur fitness costs for lac operon production (Stoebel 
et al., 2008), and graded induction is possible without the LacY permease, that would 
otherwise cause all-or-none induction of LacI-regulated promoters (Choi et al., 2008; Novick 
and Weiner, 1957). For consistency both 'wildtype' and 'gene deletion' strains were 
transformed with pCA24N-ΔpT5lac-yfp. All strains were then transformed with plasmid 
pCSλ which encodes a constitutively expressed bacterial bioluminescence operon (Kishony 
and Leibler, 2003). 
 
Drug solutions were made from powder stocks (from Sigma Aldrich unless specified 
otherwise: amikacin, A1774; ampicillin, A9518; azithromycin, Tocris 3771; bleomycin, Selleck 
S1214; carbenicillin, C1613; cephalexin, C4895; cefoxitin, C4786; cefsulodin, C8145; 
ciprofloxacin, 17850; chloramphenicol, C0378; clindamycin, Indofine C0117; colistin, C4461; 
doxycycline, D9891; erythromycin, Fluka 45673; isopropyl β-D-1-thiogalactopyranoside, 
Omega Bio-Tek AC121; kanamycin, K1876; lomefloxacin, L2906; mecillinam, 33447; 
nalidixic acid,N3143; nitrofurantoin, N7878; ortho-nitrophenyl-β-galactoside, N1127; 
penicillin G, Fluka 13750; phleomycin, P9564; polymyxin-B, P0972; rifamycin SV, 
Biochemika 83909; spectinomycin, S9007; spiramycin, S9132; streptomycin, S6501; 
sulfacetamide, S8627; sulfamethoxazole, S7507; tetracycline, 87128; tobramycin,T4014; 
triclosan, TCI America T1872; trimethoprim, T7883; vancomycin,V8138). Drug and IPTG 
gradients were made by serial dilution in M63 medium. 
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Pooled-library drug diffusion assay 
Frozen aliquots of BW25113 (deletion library host), pooled deletion library, MG1655 rph+ 
ΔlacIZYA pCA24N-ΔpT5lac-yfp (over-expression library host), or pooled over-expression 
library were thawed, and 107 cells were spread by glass beads on wet 10cm petri dishes 
containing 25mL of 1.5% agar M63 minimal media; with 15μM or 150μM IPTG only when 
plating the pooled over-expression library. Plates were briefly dried in a biosafety cabinet 
before an aliquot of antibiotic was pipetted in the center of the plate. Plates were incubated at 
37°C for 48 hours before being photographed by a custom plate imager (Chait et al., 2010). 
Plates treated with sulfacetamide and sulfamethoxazole were instead incubated for 1 week 
due to the slow growth of drug resistant colonies; in all other drugs, resistant colonies either 
appeared within 48 hours or were not apparent even after 1 week. Up to 48 drug resistant 
colonies per plate (not including wildtype reference plates) were viewed in a Nikon SMZ-
745T stereomicroscope, picked by a flame-sterilized 0.25mm nichrome wire, and struck on 
selective agar: 50 μg.mL–1 kanamycin for the gene deletion library and 30 μg.mL–1 
chloramphenicol for the gene over-expression library. Streak plates were incubated at room 
temperature for several days, a single colony from each plate was inoculated into a liquid 
culture of selective LB in a 96-well microtiter plate. Microtiter plates were incubated 
overnight at 37°C with shaking at 900 rpm, and glycerol was added to each well to a final 
concentration of 15%. Microtiter plates were stored frozen at -80°C. The genes that confer 
drug resistance to selected members of the gene over-expression library were identified by 
sending bacterial cultures to GENEWIZ to Sanger sequencing the Open Reading Frame 
(ORF) of the pCA24N plasmid using the primer ASKAseqLF (CACCATCACCATCACCAT  83
ACG). The gene deletions that confer drug resistance to selected members of the KEIO 
library were identified by Sanger sequencing the products of a 2-step hemi-nested PCR 
reaction that amplified a portion of chromosome adjacent to the Kanamycin resistance 
cassette that replaces each deleted gene. Both PCR steps used 20μL reactions with 2 units of 
OneTaq DNA Polymerase (New England Biolabs M0480), 200nM of each primer (Integrated 
DNA Technologies), and 200μM of each dNTP (New England Biolabs N0447). The first PCR 
reaction was inoculated with 1μL of liquid bacterial culture, and used the three primers 
KEIOseq1 (TGAAGTTCCTATTCCGAAGTTCCTATTCTC), CEKG2C (GGCCACGCGTC
GACTAGTACNNNNNNNNNNGATAT), and CEKG2D (GGCCACGCGTCGACTAGTAC
NNNNNNNNNNACGC) in the following reaction cycle: first 5’ at 95°C; 6 cycles of 30'' at 
95°C, 30’’ at 42°C (lowering by 1°C per cycle), 3’ at 68°C; then 24 cycles of 30’’ at 95°C, 30’’ at 
45°C, 3’ at 68°C; and finally 5’ at 68°C. The second PCR reaction was inoculated with 0.5μL 
per well of the completed first PCR reaction, and used the primers KEIOseq3 (TCGAAGCAG
CTCCAGCCTAC) and CEKG4 (GGCCACGCGTCGACTAGTAC) in the following reaction 
cycle: 30 cycles of 30'' at 95°C, 30’’ at 56°C, 3’ at 68°C; and finally 5’ at 68°C. Products of this 
final PCR reaction were sent to GENEWIZ for sequencing by the KEIOseq3 primer. 
Sequences were aligned with blastn to the E. coli MG1655 genome (NC_000913.2) to 
determine gene identity (Altschul et al., 1990; Blattner et al., 1997). Alignments that started 
more than 100 nucleotides from the expected start of alignment were discarded: gene over-
expression sequences should align shortly after the start codon of an ORF; gene deletion 
sequences should align shortly after the stop codon of an ORF. 
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Growth rate assay  
pCSλ confers constitutive bioluminescence that enables cell densities in growing cultures to 
be precisely measured over many orders of magnitude by photon counting (Kishony and 
Leibler, 2003). Cultures were grown in black 96-well plates with white wells (Perkin Elmer 
6005039) sealed with clear adhesive lids (Perkin Elmer 6005185). Wells contained 200μL of 
media inoculated with approximately 100 to 300 cells from freshly thawed -80°C frozen 
cultures. Plates were incubated in a 30°C room at 70% humidity, and growth was assayed by a 
Perkin Elmer TopCount NXT Microplate Scintillation and Luminescence Counter that 
measured each well for 1 second. Experiments of 10 to 20 plates allowed each plate to be 
measured every 30 to 60 minutes. Plate stacks were ventilated by fans to eliminate spatial 
temperature gradients and ensure uniform growth conditions across each plate. In each 
experiment, distributed throughout the plate stack were 3 control plates of uniform media 
conditions to verify the absence of growth rate gradients within plates or across the plate 
stack. Growth rate is the slope of the logarithm of photon counts per second (c.p.s.), and is 
taken from the fastest growing line of best fit observed in any 6 hour timespan; this time 
corresponds to 5 doublings of a healthy culture. The slope of the logarithm of c.p.s. is 
unaffected by changes in luminescence per cell, such as might result from antibiotic 
treatments or changes in gene expression (Kishony and Leibler, 2003).  85
Beta-galactosidase assay 
The transcription rates of genes encoded in the pCA24N plasmid at different IPTG 
concentrations were measured by kinetic beta-galactosidase (LacZ) assays of pCA24N-lacZ, 
using a method adapted from (Dodd et al., 2001). Liquid cultures of BW25113 pCA24N-lacZ 
were prepared in a 96-well plate in the same manner as for growth rate assays. The plate was 
incubated at 30ºC with shaking until the plate average OD600 equalled 0.1 (mid log phase), as 
measured by a Perkin Elmer Victor plate reader. 20μL of each well was promptly transferred 
to the corresponding well of a microtiter plate pre-warmed to 30ºC, in which each well 
contained 30μL of sterile media and 190μL of  lysis / assay buffer, consisting of 100mM Tris-
HCl pH 8.0, 1mM MgSO4, 10mM KCl, 10g.L–1 β-mercaptoethanol, 100mg.L–1 polymyxin B, 
and 850mg.L–1 ortho-nitrophenyl-β-galactoside. The lysis / assay plate was transferred to a 
Tecan Sunrise plate reader in a 30°C room at 70% humidity, and OD410 was measured every 
minute for 2 hours, with 20 seconds of shaking between each reading. For each well, 
promoter activity in Miller Units was calculated from the slope of OD410 versus time, 
multiplied by 200,000, divided by the OD600 of the culture that was transferred to that well, 
and divided by the volume (in μL) of the culture assayed (here 20μL) (Supplementary Figure 
3.2). 
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Chapter 4. 
The dependence of antibiotic resistance on target expression 
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Increased expression of a drug's target gene sometimes confers drug resistance; this can   
facilitate the evolution of drug resistance in bacteria, protozoa, and cancer, and can be used to 
identify drugs' molecular targets. However, it is unclear why this phenomena occurs with 
some drugs but not others. Here we quantitatively over-expressed Escherichia coli genes 
encoding antibiotic targets and observed that drug resistance does not only increase: it can 
remain unchanged, decrease, or first increase and then decrease. We explain these effects with 
simple models of drug action that consider toxicity from gene over-expression, and drugs that 
do not inhibit an enzyme but instead induce harmful enzyme-catalyzed reactions. The 
relation between drug resistance and target expression may reveal unexpectedly complex 
mechanisms of drug action.   90
Many drugs that inhibit an enzyme’s function can be resisted by over-expression of the gene 
encoding their target protein. For drugs where this is true, this principle has two important 
effects. Firstly, disease-causing organisms from bacteria to tumor cells can evolve strong drug 
resistance by gene amplification or over-expression of the drug’s target (Chen et al., 2009; 
Coderre et al., 1983; Flensburg and Skold, 1987; Schimke et al., 1978; Then, 1982). Secondly, 
the molecular target of the drug can be identified by a genetic screen for over-expression 
mutants that are drug resistant (Banerjee et al., 1994; Belanger et al., 1996; Luesch et al., 2005; 
Payne et al., 2004; Rine et al., 1983; Tokunaga et al., 1983). Resistance by target over-
expression is common but not universal, and despite its importance in the evolution of drug 
resistance and as a tool in drug discovery, it remains unclear why this property applies to 
some drugs but not others. Here we use antibiotics of known mechanisms in Escherichia coli 
as a case study to understand the general factors that enable or prevent the acquisition of drug 
resistance by target over-expression. 
 
The principle of resistance through target over-expression is most relevant for drugs with a 
single protein target. There are three broad mechanisms of action in which a drug does not 
act on a single protein target: (1) drugs may target multi-protein complexes (e.g. ribosome, 
RNA polymerase, or proteasome inhibitors), (2) a drug’s efficacy may rely upon 
polypharmacology (e.g. many beta-lactams and kinase inhibitors), and (3) drugs may act 
primarily upon non-protein targets (e.g. polymyxins, nitrofurans, vancomycin, DNA 
intercalators, artemisinin). It is easy to understand that for these mechanisms, resistance 
cannot result from over-expression of 'the target gene' for the simple reason that no such gene   91
can be defined. We therefore focused on drugs that primarily target a single protein and 
investigated how drug resistance changes when the target gene is over-expressed. 
 
We selected six antibiotics that primarily target a single protein, spanning a variety of 
essential targets (Table 1; for two drugs we investigated both the primary and a secondary 
target). For each drug we constructed a strain expressing the target gene from an IPTG-
inducible promoter (Figure 4.1a) (Kitagawa et al., 2005). This target over-expression strain 
was grown in liquid cultures spanning two dimensional gradients of drug-dose and IPTG-
induced gene expression; the latter was quantified by beta-galactosidase assays of a strain 
expressing  lacZ in place of a drug target (Supplementary Figure 4.1). A sensitive 
bioluminescence-based assay was used to measure bacterial growth rates and thereby to 
determine how drug susceptibility is altered as a function of target gene expression. 
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Table 1. List of drugs and drug targets utilized in this study. * indicates primary target 
when there is a secondary target of lower affinity or lesser importance to growth (Drlica and 
Zhao, 1997; Kong et al., 2010). 
 
 
 
Over-expression of a drug's target gene had qualitatively different effects on drug resistance 
for different drugs (Figure 4.1b). The drug concentration that inhibits growth by 50% (IC50) 
was increased by expressing the targets of trimethoprim (DHFR) and triclosan (ENR), and 
decreased when expressing the targets of cefsulodin (PBP1A, PBP1B) and ciprofloxacin 
(Gyrase, Topo IV). Resistance to sulfamethoxazole, a sulfonamide-class antibiotic, was 
independent of its target (DHPS) expression level, and most curiously, the IC50 of 
mecillinam increased with mild over-expression of its target (PBP2) but decreased with 
stronger over-expression. 
Drug name  Target  Target function  Target process  Gene 
Trimethoprim  DHFR  Dihydrofolate reductase  Folate synthesis  folA 
Sulfamethoxazole  DHPS  Dihydropteroate synthase  Folate synthesis  folP 
Triclosan  ENR  Enoyl acyl carrier protein reductase  Fatty acid synthesis  fabI 
Ciprofloxacin 
Gyrase * 
Topo IV 
DNA gyrase 
Topoisomerase IV 
DNA replication 
gyrA 
parC 
Cefsulodin 
PBP1A 
PBP1B * 
Murein polymerase 
Murein polymerase 
Cell wall synthesis 
mrcA 
mrcB
Mecillinam  PBP2 Peptidoglycan  transpeptidase  Cell wall synthesis  mrdA   93
 
 
 
 
 
 
 
 
Figure 4.1. Over-expression of a drug’s target gene can increase, decrease, or have no 
effect on drug resistance. (a) E. coli strains were constructed with IPTG adjustable over-
expression of drug target genes. (b) For each drug-gene pair, bacterial growth rates were 
measured over gradients of drug dose (vertical axis) and IPTG-induced gene dose (horizontal 
axis). Additional target expression is quantified in Miller Units (MU) from kinetic beta-
galactosidase assays of a matching plasmid encoding lacZ (Supplementary Figure 4.1). 
Heatmap color indicates growth rate, from uninhibited growth (yellow) to no growth (black). 
WT denotes a strain without any additional drug target expression, since its plasmid contains 
neither a promoter nor a drug target gene. At each level of gene expression, the drug 
concentration that inhibits growth to 50% of the uninhibited wildtype growth (IC50) is 
overlaid in white.   94
 
 
 
 
 
 
 
 
 
Figure 4.1. Over-expression of a drug’s target gene can increase, decrease, or have no 
effect on drug resistance. (Continued)   95
There was no trend within target pathways as to which target genes conferred drug resistance 
upon over-expression; for example both DHPS and DHFR are enzymes in the folate 
biosynthesis pathway, but only DHFR confers resistance to its inhibitor when over-expressed. 
These observations are consistent with clinical isolates of drug resistant bacteria: 
trimethoprim resistant mutants have been reported with promoter mutations and elevated 
DHFR expression (Flensburg and Skold, 1987; Then, 1982), but DHPS regulatory mutations 
have not been reported in sulfonamide resistant mutants, despite characterization of many 
resistant mutants (Skold, 2000). Similar supportive results have also been observed for 
triclosan where resistant mutants have been found with elevated ENR expression (Chen et al., 
2009), and for ciprofloxacin where, while amino acid changes in Gyrase and Topoisomerase 
IV are associated with resistance, no regulatory mutations have been reported (Ruiz, 2003). 
 
We sought to understand the relation between drug resistance and drug target expression 
levels using simple mathematical models of the fitness costs of gene expression and enzyme 
inhibition. We define the target enzyme concentration as the sum of a wildtype level of 
enzyme (Ewt) and an additional amount (Eadditional) .  W e  b u i l t  m a s s  a c t i o n  m o d e l s  o f  
competitive and non-competitive inhibition and calculated drug susceptibility under the 
simplifying assumption that 50% growth inhibition (IC50) occurs when the net flux through 
an essential enzyme is 50% inhibited. Both the competitive and non-competitive inhibition 
models yield a linear dependence of IC50 on the fold over-production of the enzyme: 
IC50/IC50wt = 2×(Ewt+Eadditional) / Ewt  −1 (Figure 4.2a, h–; Supplementary Figure 4.2a,b). For 
example, if the enzyme is over-expressed 100-fold then 99.5% of the enzyme will have to be   96
inhibited in order to have half of the flux of the wild-type, which will require 200 times more 
drug. We observed that many drug targets incurred small to lethal fitness costs when over-
expressed, even in the absence of drug (Figure 4.1b). When the models include the fitness cost 
of over-expression as an independent mechanism of toxicity (treated as a second drug that is 
'Bliss additive' with the actual drug(Bliss, 1939)), we find that 
IC50/IC50wt = 2×(Ewt+Eadditional) / Ewt × (1 - cost(Eadditional) −1 (Figure 4.2a, h–c+; Supplementary 
Figure 4.2a,b). This simple model quantitatively explains the increase in resistance from over-
expressing the targets of both trimethoprim (DHFR) and triclosan (ENR) (Figure 4.2b, h–c–), 
as well as the increase and subsequent decrease in IC50 resulting from over-expression of 
mecillinam's target (PBP2) (Figure 4.2b, h–c+). Thus, drug target over-expression can confer 
resistance by compensating for inhibited target genes, but the potential for resistance may be 
limited if target gene over-expression is costly. Additionally, the level of resistance depends 
on the magnitude of Ewt, which can explain the differences between trimethoprim and 
triclosan (Supplementary Figure 4.3).  
 
If drug target over-expression induces large fitness costs before there is a significant fold-
increase in expression, then there might be no expression level that increases drug resistance. 
This alone might explain the lack of resistance from over-expressing the targets of 
ciprofloxacin and cefsulodin, but it cannot explain the absence of sulfamethoxazole 
resistance, whose target DHPS incurs no significant fitness cost upon over-expression. 
Sulfonamide antibiotics inhibit the synthesis of dihydropteroate from pteridine diphosphate   97
and para-aminobenzoic acid (PABA) by competing with PABA for binding to the enzyme 
DHPS(Brown, 1962). Interestingly, sulfonamides do not simply inhibit DHPS, but are 
covalently attached to pteridine diphosphate in place of PABA, yielding a dihydropterin-
sulfonamide product (Bock et al., 1974; Roland et al., 1979) (Supplementary Figure 4.4). 
While dihydropterin-sulfonamide is not toxic to E. coli (Roland et al., 1979), this reaction is 
harmful to growth by depleting the essential metabolite pteridine diphosphate. We modeled 
this system treating pteridine diphosphate as being synthesized at a constant rate by the 
upstream folate synthesis enzymes, and consumed by DHPS-catalyzed condensation to 
dihydropteroate or dihydropterin-sulfonamide. Strikingly, this model shows that when a drug 
induces a harmful enzyme-catalyzed reaction with a rate-limiting substrate, pathway 
inhibition is independent of the enzyme concentration (Figure 4.2a, h+; Supplementary Figure 
4.2c). Taking sulfonamides as an example, the fraction of pteridine diphosphate that is 
converted to the correct product dihydropteroate is defined not by the abundance of 
uninhibited enzyme, but only by the ratio of sulfonamide to PABA. This result is consistent 
with the observation that increased PABA synthesis confers sulfonamide resistance (Landy et 
al., 1943) and explains why, in contrast, increased expression of DHPS confers no protection 
against a sulfonamide (Figure 4.2b, h+c–). Sulfonamides may thus be more accurately 
described as poisons that deplete pteridine diphosphate, rather than inhibitors of DHPS. 
While this modeling framework is not appropriate to describe the DNA damage that results 
from the binding of ciprofloxacin to Gyrase or Topo IV near the DNA replication fork, it 
nonetheless illustrates a principle that applies to ciprofloxacin and other drugs: drugs that   98
only inhibit an enzyme's catalytic activity may be resisted by additional enzyme production, 
while drugs that induce an enzyme to catalyze harmful reactions will not be resisted by an 
excess of that enzyme; to this category belongs antibiotics such as aminoglycosides (Davis, 
1987), fluoroquinolones (Pan et al., 2001), and sulfonamides. Indeed, the over-expression of a 
drug target that does not confer resistance but does incur fitness costs will only decrease drug 
resistance (Figure 4.2b, h+c+).   99
 
 
Figure 4.2. Over-expression of drug target genes can confer both resistance and fitness 
costs, resulting in diverse changes in drug resistance. a, Mass-action models of enzyme 
inhibition quantified the relation between drug concentration, growth inhibition, and enzyme 
expression (wildtype enzyme abundance = Ewt, additional enzyme = Eadditional). Drug-induced 
growth inhibition and fitness costs due to gene over-expression are treated as independent 
mechanisms of toxicity. Changes in the drug concentration that inhibits growth by 50% 
(IC50) are found to depend upon two factors: whether drug binding only inhibits the enzyme 
(h–) or also induces harmful reactions when bound (h+), and the degree of fitness costs from 
additional drug target expression; for example lethal, partial, or no fitness costs (c+ lethal 
/ c+partial  / c–). Mechanistic models demonstrate that drug target over-expression protects 
against enzyme inhibitors (h–), but not against drugs that damage an enzyme's substrate (h+) 
(Supplementary Figure 4.2). b, The theory presented in (a) results in diverse changes in drug 
resistance as drug targets are over-expressed. Possible changes in drug resistance upon drug 
target over-expression include an increase, decrease, first increase then decrease, or no 
change; differences in Ewt influence the level of resistance that may be achieved. This theory 
rationalizes the diverse experimentally observed behaviors (IC50 lines from Figure 4.1b). 
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Figure 4.2. Over-expression of drug target genes can confer both resistance and fitness 
costs, resulting in diverse changes in drug resistance. (Continued)   101
This study shows that increasing the expression of drug’s target gene can have a wide range of 
effects on resistance to that drug; the simple expectation that resistance will monotonically 
increase is one of several possibilities. These diverse effects can be understood as the result of 
two factors: firstly whether a drug solely inhibits a beneficial reaction or induces a harmful 
reaction; and secondly whether drug target over-expression incurs fitness costs. These results 
suggest that efforts to identify the molecular targets of compounds by searching for drug 
resistance via target over-expression will, for better or worse, yield predictably biased results. 
This approach will succeed in identifying the targets of compounds that are strictly an 
inhibitor of a single non-costly gene, but may fail for compounds that inhibit costly genes, 
that act upon multiple targets, or that induce harmful reactions such as damaging a substrate. 
However, unexpectedly complex mechanisms of drug action can be revealed if the over-
expression of a known drug target fails to confer resistance. Finally, these results suggest that 
the development of compounds that inhibit costly genes, or that inhibit a pathway by 
damaging pathway-essential metabolites, will produce drugs less prone to the evolution of 
resistance through target over-expression. 
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Methods 
Strains and Media 
E. coli strain BW25113 was the host for all studies(Datsenko and Wanner, 2000). As lacZYA is 
deleted in BW25113, IPTG does not incur fitness costs for lacZYA production(Stoebel et al., 
2008), and graded induction is possible without the LacY permease, that would otherwise 
cause all-or-none induction of LacI-regulated promoters(Choi et al., 2008; Novick and 
Weiner, 1957). BW25113 was transformed with plasmid pCSλ, encoding a constitutively 
expressed bacterial bioluminescence operon(Kishony and Leibler, 2003). Plasmids encoding 
each target gene (in a pCA24N backbone) were obtained from the ASKA E. coli Open 
Reading Frame collection(Kitagawa et al., 2005), sequenced to confirm gene identity, and 
were transformed into BW25113 pCSλ. The cefsulodin target gene PBP1B (mrcB) was not 
found at the expected position in the ASKA collection, and was instead isolated by plating a 
pooled mixture of the entire ASKA collection on 1.5% agar plates of Luria Bertani broth with 
a range of isopropyl β-D-1-thiogalactopyranoside (IPTG) concentrations, and screening for 
colonies resistant to a 100μg point source of cefsulodin. At 15μM IPTG, many mildly resistant 
colonies were isolated that carried pCA24N plasmids encoding PBP1B, according to 
sequencing. This IPTG concentration corresponds to the point in Figure 4.1B where PBP1B 
over-expression confers modest cefsulodin resistance. Wildtype drug susceptibilities were 
determined using a matching strain with no additional drug target gene expression; BW25113 
pCSλ pCA24N-Δpromoter-yfp; where the IPTG-inducible promoter in pCA24N had been 
deleted, and yellow fluorescent protein was encoded in place of a drug target gene. All   104
experiments were performed in M63 minimal medium (2g.L–1 (NH4)2SO4, 13.6g.L–1 KH2PO4, 
0.5mg.L–1 FeSO4•7H2O, adjusted to pH 7.0 with KOH) supplemented with 0.2% glucose, 
0.01% casamino acids, 1mM MgSO4 and 0.5mg.L–1 thiamine, and also 10mg.L–1 
chlorampenicol and 25mg.L–1 kanamycin for the maintenance of the pCA24N and pCSλ 
plasmids, respectively. Drug solutions were made from powder stocks (from Sigma Aldrich 
unless otherwise specified: cefsulodin, C8145; chloramphenicol, C0378; ciprofloxacin, 17850; 
isopropyl β-D-1-thiogalactopyranoside (IPTG), Omega Bio-Tek AC121; kanamycin, K1876; 
mecillinam, 33447; ortho-nitrophenyl-β-galactoside, N1127; polymyxin-B, P0972; 
sulfamethoxazole, S7507; triclosan, TCI America T1872; trimethoprim, T7883). Drug and 
IPTG gradients were made by serial dilution in M63 medium. 
 
Growth rate assay  
The constitutive bioluminescence that results from pCSλ enables cell densities in growing 
cultures to be precisely measured over many orders of magnitude by photon 
counting(Kishony and Leibler, 2003). Cultures were grown in black 96-well plates with white 
wells (Perkin Elmer 6005039) sealed with clear adhesive lids (Perkin Elmer 6005185). Wells 
contained 200μL of media inoculated with approximately 100 to 300 cells from freshly thawed 
-80°C frozen cultures. Plates were grown in a 30°C room at 70% humidity, and growth was 
assayed by a Perkin Elmer TopCount NXT Microplate Scintillation and Luminescence 
Counter that measured each well for 1 second. Experiments of 10 to 16 plates allowed each 
plate to be measured every 30 to 50 minutes. Plate stacks were ventilated by fans to eliminate 
spatial temperature gradients and ensure uniform growth conditions across each plate. In   105
each experiment, distributed throughout the plate stack were 3 control plates of uniform 
media conditions to verify the absence of growth rate gradients within plates or across the 
plate stack. Growth rate is the slope of the logarithm of photon counts per second (c.p.s.), and 
is taken from the fastest growing line of best fit observed in any 6 hour timespan; this time 
corresponds to 5 doublings of a healthy culture. The slope of the logarithm of c.p.s. is 
unaffected by changes in luminescence per cell, such as might result from antibiotic 
treatments or changes in gene expression(Kishony and Leibler, 2003). 
 
Beta-galactosidase assay 
The transcription rates of genes encoded in the pCA24N plasmid at different IPTG 
concentrations were measured by kinetic beta-galactosidase (LacZ) assays of pCA24N-lacZ, 
using a method adapted from (Dodd et al., 2001). Liquid cultures of BW25113 pCA24N-lacZ 
were prepared in a 96-well plate in the same manner as for growth rate assays. The plate was 
incubated at 30ºC with shaking until the plate average OD600 equalled 0.1 (mid log phase), as 
measured by a Perkin Elmer Victor plate reader. 20μL of each well was promptly transferred 
to the corresponding well of a microtiter plate pre-warmed to 30ºC, in which each well 
contained 30μL of sterile media and 190μL of  lysis / assay buffer, consisting of 100mM Tris-
HCl pH 8.0, 1mM MgSO4, 10mM KCl, 10g.L–1 β-mercaptoethanol, 100mg.L–1 polymyxin B, 
and 850mg.L–1 ortho-nitrophenyl-β-galactoside. The lysis / assay plate was transferred to a 
Tecan Sunrise plate reader in a 30°C room at 70% humidity, and OD410 was measured every 
minute for 2 hours, with 20 seconds of shaking between each reading. For each well,   106
promoter activity in Miller Units was calculated from the slope of OD410 versus time, 
multiplied by 200,000, divided by the OD600 of the culture that was transferred to that well, 
and divided by the volume (in μL) of the culture assayed (here 20μL) (Supplementary Figure 
4.1).  107
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Supplementary Material for Chapter 1. 
Chemical decay of an antibiotic inverts selection for resistance 
 
 
 
 
Supplementary Figure 1.1. Absorbance spectra and structures of tetracycline and its 
degradation products. Absorbance spectra measured in aqueous solution, at 10μg/mL, of 
tetracycline (Tet; gray), epitetracycline (ETC; cyan), anhydrotetracycline (ATC; magenta) and 
epianhydrotetracycline (EATC; dark blue).   111
 
 
 
 
 
Supplementary Figure 1.2. Measured and modeled spectra of degraded tetracycline 
solutions. Measured spectra of tetracycline solutions exposed to degrading conditions for 
different lengths of time (black), aligned with modeled spectra (gray). Modeled spectra are 
calculated as a linear combination of the spectra of individual compounds (Supplementary 
Figure 1.1), with coefficients given by the kinetic model of tetracycline decay (Supplementary 
Figure 1.3), which describes the proportion of each compound as a function of time in 
degrading conditions (see Figure 1.1c). After very prolonged degradation (tdeg = 2500 min) the 
spectrum is flat but non-zero, and so the linear combination of spectra also contains a term 
for the tdeg =2500 min spectrum, with coefficient given by the proportion of further 
degradation products, i.e. following further decay of ATC and EATC (denoted “∅” in the 
kinetic model; Supplementary Figure 1.3). The parameter kloss is fitted to minimize the sum of 
square errors between these measured and modeled spectra. To maximize distinction 
between the similar spectra of epimers, errors were only summed over the most characteristic 
absorption peaks, located at the wavelength ranges 250-290nm and 325-400nm. 
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Supplementary Figure 1.2. Measured and modeled spectra of degraded tetracycline 
solutions. (Continued)   113
 
 
 
Supplementary Figure 1.3. Kinetic model of tetracycline decay. Reaction scheme for the 
kinetic model of tetracycline decay constructed by (Yuen and Sokoloski, 1977), extended to 
account for the slow loss of degradation products at very long timescales (kloss). The shaded 
areas in Figure 1.1c are constructed from this model, utilizing values of k1, k-1, k2, k-2, k3 and k4 
which were experimentally determined by (Yuen and Sokoloski, 1977), and a fitted value of 
kloss (Supplementary Table 1.1). 
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Supplementary Figure 1.4. Parameter sensitivity of the kinetic model of tetracycline 
decay. Plotting the error between measured and modeled spectra of degraded tetracycline 
solutions (Supplementary Figure 1.2) demonstrates the consistency of the rate constants 
measured by (Yuen and Sokoloski, 1977) with this study. Note that only the characteristic 
wavelength ranges 250-290nm and 325-400nm were utilized. The parameter values used in 
the kinetic model (Supplementary Table 1.1) are marked in red. kloss was absent from the 
kinetic model of (Yuen and Sokoloski, 1977), and so was fitted to minimize the sum of square 
errors.   115
 
 
Supplementary Figure 1.4. Parameter sensitivity of the kinetic model of tetracycline 
decay.  (Continued) 
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Supplementary Figure 1.5. TetS and TetR strains have equal growth rates in the absence of 
tetracycline.  Growth rates were measured with high resolution over the course of 15 
doublings using bioluminescence based measurements of cell density (Kishony and Leibler, 
2003; Yeh et al., 2006) (Methods). Six representative growth curves each are presented for the 
TetS (green) and TetR (red) strains. Inset: Boxplot of growth rate measurements of the TetS 
and TetR strains (n=36 each). 
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Supplementary Figure 1.6. Tetracycline degradation products and fusaric acid select 
against chromosomally-integrated tetracycline resistance. The cost of expression of 
tetracycline resistance is dependent upon the dosage of resistance genes(Lenski et al., 1994; 
Moyed et al., 1983). We have observed that Tet degradation products select against resistance 
(Fig 2c,d) when resistance is provided from a plasmid whose level of expression of the tetA 
efflux pump maximizes fitness in 10μg/mL Tet (Daniels and Bertrand, 1985; Lenski et al., 
1994); Methods). When tetracycline resistance is supplied by a lower dosage of resistance 
genes, the extent of selection against resistance will presumably be weaker, as the phenotype 
approaches that of a fully sensitive strain. We therefore measured the effect Tet degradation 
products on competition between sensitive and resistant strains, when the Tn10 tetracycline 
resistance determinant was integrated in single-copy in the chromosome. In this scenario we 
can reproduce the net selection against resistance seen in Figure 1.2c,d (trajectory 1) when 
Tet degradation products (initial Tet concentration 2000 ng/mL) are supplied together with 
40 μg/mL fusaric acid, a naturally-occurring compound which sensitizes bacteria to the 
expression of the tetA efflux pump(Bochner et al., 1980). Fold change in Ntet
S / Ntet
R is 
determined relative to wells lacking Tet or its degradation products, but containing fusaric   118
acid (Methods), and so excludes the selection imposed by fusaric acid alone, but reflects its 
combined effect with Tet and Tet degradation products. Fusaric acid is produced by many 
species of the Fusarium fungi (Bacon et al., 1996) and thus may be an ecologically relevant 
factor contributing to selection against low-copy or high-copy tetracycline resistance. In poor 
nutritional conditions and specific salt concentrations, fusaric acid can be made to select 
against tetracycline resistance in Salmonella typhimurium and Escherichia coli (Bochner et al., 
1980; Maloy and Nunn, 1981). In these rich nutritional conditions, fusaric acid combined 
with undegraded tetracycline continues to select for resistance, but as tetracycline degrades, 
the combination of fusaric acid and decay products selects against resistance. This 
demonstrates that degradation influences the interaction between an antibiotic and its decay 
products (collectively) with other compounds which may conditionally select against 
resistance.   119
 
 
 
Supplementary Figure 1.7. Net selection for/against tetracycline resistance depends upon 
both the means of drug loss and the initial drug concentration. For any given initial drug 
concentration and rates of dilution and degradation (λdil and λdeg, respectively), a linear 
trajectory is defined across the surface of Figure 1.2c, describing how selective pressure 
changes over time as the drug and its degradation products are lost from the environment: 
examples are trajectories 1, 2, and 3 from Figures 1.2c and 1.2d. Integrating log(NTet
S / NTet
R) 
along a trajectory provides the net selective pressure resulting from a given initial drug 
concentration and ratio of dilution and degradation rates, λdil / λdeg. On the left edge of the 
plot drug loss is by degradation only, with the dilution rate increasing in relative magnitude 
towards the right; on the right edge drug loss is by dilution only. Trajectory 1 illustrates a 
timecourse of selection resulting in net selection against resistance. Trajectory 2 illustrates 
neutral net selection, where periods of selection for and against resistance cancel out over 
time. Trajectory 3 illustrates net selection for resistance.   120
 
 
 
 
Supplementary Figure 1.7. Net selection for/against tetracycline resistance depends upon 
both the means of drug loss and the initial drug concentration. (Continued)   121
 
 
 
 
 
 
Supplementary Figure 1.8. Tetracycline and its degradation products each have a different 
impact on selection for resistance. Selective pressures of Tet and individual degradation 
products ETC, ATC, and EATC, measured by competition between TetS and TetR strains (see 
Figure 1.2a).    122
 
 
 
 
 
Supplementary Figure 1.9. Combinations of tetracycline and its degradation products 
produce selective pressures which are well predicted by Bliss additivity. Selective pressure 
for (red) or against (green) resistance across a drug gradient of Tet and a 1:1 mixture of ATC 
and EATC; on the left experimentally measured (as per Figure 1.2a) and on the right 
(‘Additive Model’) calculated from the effects along the axes of the ‘Experimental’ panel, 
assuming additive drug interactions, i.e. by summing the changes in log(NTet
S / NTet
R).   123
 
 
 
Supplementary Figure 1.10. Different permutations of fluorescent labels do not influence 
selection for/against resistance by tetracycline degradation products. Selective pressure for 
(red) or against resistance (green) by Tet and its degradation products (Figure 1.2c) was 
measured by averaging the results of two competition experiments: between TetS-CFP and 
TetR-YFP; and between TetS-YFP and TetR-CFP. Here these measurements are presented 
separately, where it can be seen that competition between TetS and TetR strains is not 
influenced by the permutation of fluorescent labels.    124
 
 
 
 
 
 
Supplementary Figure 1.11. Measurement of selection for/against resistance by flow 
cytometry. Flow cytometry measurements of NTet
S and NTet
R, for representative data points in 
Figure 1.2c (reproduced here with selected data points marked in purple). These scatter plots 
of raw measurements of cyan and yellow fluorescence are presented in ‘logicle’ scale to 
prevent distortion of low signals by logarithmic scaling(Parks et al., 2006). These points 
demonstrate selection for resistance (circle), no selection (triangle), and selection against 
resistance (square). Above the cyan-yellow scatter plots are histograms summing the number 
of resistant cells (red; NTet
R) and sensitive cells (green; NTet
S). 
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Supplementary Figure 1.11. Measurement of selection for/against resistance by flow 
cytometry. (Continued)   126
Supplementary Table 1.1. Parameter values of the kinetic model of tetracycline decay 
 
 
 
 
 
 
 
The consistency of parameters measured in (Yuen and Sokoloski, 1977) with this study’s 
spectra of degraded tetracycline solutions (Supplementary Figure 1.2) can be quantitated by 
the error in the alignment between measured and modeled spectra. Specifically, we define the 
error E as  
   , 
where λ is integrated over the ranges 250-290nm and 325-400nm. E can be evaluated with 
modeled spectra produced either by the parameters in (Yuen and Sokoloski, 1977), or by 
parameters which are fitted to minimize E. For each single parameter then, we determine 
ΔE = E  ((Yuen and Sokoloski, 1977)  parameter)  /  E(best fit parameter)  -1,  which  describes 
how close the parameters in (Yuen and Sokoloski, 1977) are to minimizing E. We see that 
they are indeed extremely close to minimizing the alignment error (see also Supplementary 
Figure 1.4). When all parameters are simultaneously fitted, ΔE  =  2%. Values taken from 
(Yuen and Sokoloski, 1977) are averages of duplicate measurements at 75°C. Note that 
Parameter 
Value 
(min-1) 
Source  ΔE (%) 
  k1  0.0265  (Yuen and Sokoloski, 1977)  0.04 
  k-1  0.0207  (Yuen and Sokoloski, 1977)  0.04 
  k2  0.0317  (Yuen and Sokoloski, 1977)  0.06 
  k-2  0.0352  (Yuen and Sokoloski, 1977)  0.08 
  k3  0.0209  (Yuen and Sokoloski, 1977)  0.09 
  k4  0.0169  (Yuen and Sokoloski, 1977)  0.001 
  kloss  0.00147  fitted*  N/A*   127
although Tet and ATC exert the strongest selective effects (Supplementary Figure 1.8), the 
kinetic model cannot be accurately simplified to these two compounds alone. The 
equilibrium constant for epimerization between Tet and ETC (k1/k-1 = 1.3) is different from 
the equilibrium constant between ATC and EATC (k2/k-2 = 0.90). Consequently, even after 
epimerization reactions have reached equilibrium, the dehydration reaction does not bring 
about a net 1:1 conversion between Tet and ATC.   128
Supplementary Material for Chapter 2. 
A multi-peaked adaptive landscape arising from high-order genetic 
interactions 
 
Supplementary Figure 2.1. Growth rates of E.coli strains with mutant DHFR genes as a 
function of trimethoprim concentration. The growth rates of strains carrying all possible 
combinations of seven trimethoprim resistance-conferring mutuations were measured across 
a range of trimethoprim concentrations. Each column is one strain, whose mutations are 
indicated in the color coded grid atop the plot. Mutant strains are sorted by the overall 
number of mutations. A black to yellow heatmap indicates growth rate. Six columns that are 
entirely black are genotypes that could not be successfully integrated into the chromosome of 
E.coli despite repeated attempts.   129
      
Supplementary Figure 2.1. Growth rates of E.coli strains with mutant DHFR genes as a 
function of trimethoprim concentration. (Continued)  130
Supplementary Material for Chapter 3. 
Diverse pathways to drug resistance by changes in gene expression 
 
Supplementary Figure 3.1. Pooled diffusion-based selection for changes in gene 
expression that confer antibiotic resistance. 107 colony forming units of a clonal wildtype 
strain or a pooled library of gene deletion or gene over-expression mutants were plated on 
M63 glucose minimal media agar. An aliquot of antibiotic was added to the center and plates 
were incubated for 48 hours at 37°C before imaging. Images here show the presence of gene 
expression mutants with resistance to antibiotics that act upon: a, cell wall synthesis; b, the 
cell membrane; c, transcription; d, e, translation; f, DNA synthesis; g, free radical production. 
Plates treated with sulfacetamide and sulfamethoxazole were incubated for 1 week before 
imaging due to the slow growth of sulfonamide resistant colonies.   131
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Supplementary Figure 3.1 (continued).   135
 
Supplementary Figure 3.1 (continued).   136
 
Supplementary Figure 3.1 (continued). 
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Supplementary Table 3.1. Changes in gene expression that increase antibiotic resistance. 
Gene-drug interactions from Figure 3.2 are tabulated with gene functions curated from the 
Ecocyc database (Keseler et al., 2011) 
Supplementary Table 3.1. Changes in gene expression that increase antibiotic resistance. (continued) 
1
3
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Change in 
gene 
expression 
Gene 
name 
Drugs resisted  Gene function 
Previously 
associated 
with drug 
resistance? 
Notes 
Overexpression  hemD 
AMK, MEC, PHM, 
TOB 
uroporphyrinogen III synthase  N   
Overexpression  yhbT  AMK, PHM, TOB  predicted lipid carrier protein  N   
Overexpression  ampC 
AMP, CLX, CRB, 
FOX, PEN 
β-lactamase  Y  (Linstrom et al., 1970) 
Overexpression  marA 
AMP, BLM, CLI, 
CLX, CPR, DOX, 
ERY, NAL, PEN, 
TET 
MarA DNA-binding transcriptional 
dual regulator 
Y  (Cohen et al., 1993) 
Overexpression  nanA  AMP  N-acetylneuraminate lyase  N 
nanA is the first enzyme in pathway for degradation 
of sialic acid (Vimr and Troy, 1985). 
Overexpression  soxS 
AMP, AZI, BLM, 
CLI, CPR, DOX, 
ERY, FOX, NAL, 
PEN, SPR, TET, 
TMP 
SoxS DNA-binding transcriptional 
dual regulator 
Y  (Amabile-Cuevas and Demple, 1991) 
Overexpression  yidF  AMP, CLX, PEN 
predicted DNA-binding 
transcriptional regulator 
N   
Overexpression  gadW  AZI, BLM 
GadW DNA-binding transcriptional 
dual regulator 
N 
gadW is a regulator of Glutamic acid decarboxylase 
(GAD) acid resistance system (Tucker et al., 2003). 
Overexpression  rpmH  AZI, ERY, SPR  50S ribosomal subunit protein L34  N 
Overexpression of rpmH decreases the production of 
polyamine (Panagiotidis et al., 1995). 
Overexpression  ydeO  AZI 
YdeO DNA-binding transcriptional 
dual regulator 
N 
ydeO activates transcription of acid resistance genes 
(Masuda and Church, 2003).  
Supplementary Table 3.1. Changes in gene expression that increase antibiotic resistance. (continued) 
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Change in 
gene 
expression 
Gene 
name 
Drugs resisted  Gene function 
Previously 
associated 
with drug 
resistance? 
Notes 
Overexpression  yeaH  AZI, ERY, SPR  conserved protein  N   
Overexpression  sbmC  BLM, PHM  DNA gyrase inhibitor  Y 
Overexpression of sbmC confers resistance to 
mitomycin C (Wei et al., 2001) and microcin B17 
(Baquero et al., 1995). 
Overexpression  yjcH  BLM  conserved inner membrane protein  N   
Overexpression  ddpF 
CFS, CLX, MEC, 
PHM 
putative ATP-binding component of 
an ABC transporter
N 
While ddpF overexpression resists CFS, CLX, MEC, 
PHD, ddpF deletion resists AMK
Overexpression  degQ  CFS  serine endoprotease  N   
Overexpression  mrcB  CFS  Murein polymerase (PBP1b)  Y 
mrcB and mrcA are the primary targets of Cefsulodin 
(Kong et al., 2010). 
Overexpression  nlpE  CFS, CRB, PEN  outer membrane lipoprotein  N   
Overexpression  adk  CLI  adenylate kinase  N   
Overexpression  cadA  CLI  lysine decarboxylase 1  N 
cadA is part of the lysine-dependent acid resistance 
system 4 (Takayama et al., 1994). 
Overexpression  hflX  CLI, ERY 
GTPase associated with the 50S 
subunit of the ribosome 
N   
Overexpression  lepA  CLI  elongation factor 4  N   
Overexpression  proQ  CLI  RNA chaperone  N   
Overexpression  ybiT  CLI 
putative ATP-binding component of 
an ABC transporter 
N    
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expression 
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name 
Drugs resisted  Gene function 
Previously 
associated 
with drug 
resistance? 
Notes 
Overexpression  yheS  CLI 
putative ATP-binding component of 
an ABC transporter 
N   
Overexpression  aroB  CLX  3-dehydroquinate synthase  N   
Overexpression  bssR 
CLX, CPR, FOX, 
NIT 
regulator of biofilm formation  N   
Overexpression  gmr 
CLX, FOX, NIT, 
PEN 
modulator of RNase II stability  N   
Overexpression  gntT  CLX  gluconate transporter  N   
Overexpression  nanK  CLX, FOX  N-acetylmannosamine kinase  N   
Overexpression  rcsD  CLX 
Regulator of capsular polysaccharide 
synthesis
N   
Overexpression  rluA  CLX 
23S rRNA and tRNA pseudouridine 
synthase 
N   
Overexpression  yccT  CLX, PEN, VAN  conserved protein  N   
Overexpression  yjjQ  CLX, PEN 
predicted DNA-binding 
transcriptional regulator 
N 
yjjQ is associated with methylglyoxal sensitivity (Kim 
et al., 2007). 
Overexpression  rbsR  CPR, FOX, PEN 
'Ribose Repressor' DNA-binding 
transcriptional repressor 
N   
Overexpression  baeR  CRB  BaeR transcriptional regulator  Y 
baeR activates the MdtABC drug efflux system 
(Nagakubo et al., 2002). 
Overexpression  iap  CRB, PEN 
alkaline phosphatase isozyme 
conversion protein 
N    
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Overexpression  amiA  ERY, SPR 
N-acetylmuramoyl-L-alanine 
amidase 1 
N   
Overexpression  appY  ERY 
'acid phosphatase' DNA-binding 
transcriptional activator 
N   
Overexpression  rluE  ERY, SPR  23S rRNA pseudouridine synthase  N   
Overexpression  rng  ERY  ribonuclease G  N   
Overexpression  btuE  FOX  thioredoxin/glutathione peroxidase  N   
Overexpression  ycgZ  FOX, PEN  predicted protein  N 
ycgZ is a member of the cold shock stimulon (Polissi 
et al., 2003). 
Overexpression  dxs  MEC 
1-deoxyxylulose-5-phosphate 
synthase 
N 
Dxs is the first enzyme in the methylerythritol 
phosphate pathway of isoprenoid biosynthesis 
(Sprenger et al., 1997). 
Overexpression  gcvA  MEC 
'Glycine cleavage A' DNA-binding 
transcriptional dual regulator 
N   
Overexpression  glnB  MEC  nitrogen regulatory protein P-II 1  N   
Overexpression  glyQ  MEC  glycyl-tRNA synthetase, α subunit  N   
Overexpression  mrdA  MEC  peptidoglycan synthetase (PBP2)  Y 
mrdA is the primary target of Mecillinam (Kong et 
al., 2010). 
Overexpression  rplJ  MEC  50S ribosomal subunit protein L10  N   
Overexpression  rutR  MEC, PEN 
'pyrimidine utilization, rut 
repressor' DNA-binding 
transcriptional dual regulator 
N    
Supplementary Table 3.1. Changes in gene expression that increase antibiotic resistance. (continued) 
1
4
2
 
Change in 
gene 
expression 
Gene 
name 
Drugs resisted  Gene function 
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Notes 
Overexpression  trpR  MEC  tryptophan transcriptional repressor  N   
Overexpression  yehK  MEC  predicted protein  N   
Overexpression  ygbE  MEC  conserved inner membrane protein  N   
Overexpression  ycjR  NIT 
predicted component of the SdsRQP 
multidrug efflux pump
Y  (Dinh et al., 1994) 
Overexpression  yibF  NIT  glutathione transferase-like protein  N   
Overexpression  eptB  PEN, VAN  phosphoethanolamine transferase  N 
eptB modifies lipopolysaccharide (Reynolds et al., 
2005). 
Overexpression  nadK  PEN  NAD kinase  N   
Overexpression  cpdA  PHM  cAMP phosphodiesterase  N 
Overproduction of cpdA confers acid resistance 
(Barth et al., 2009). 
Overexpression  frsA  PHM 
fermentation/respiration switch 
protein
N   
Overexpression  metB  PHM 
O-succinylhomoserine lyase / 
O-succinylhomoserine(thiol)-lyase 
N   
Overexpression  pdhR  PHM 
pyruvate dehydrogenase complex 
DNA-binding transcriptional dual 
regulator 
N   
Overexpression  slyA  PHM 
SlyA DNA-binding transcriptional 
activator 
N   
Overexpression  yejG  PHM  predicted protein  N    
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with drug 
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Notes 
Overexpression  ylcG  PHM 
DLP12 prophage; small membrane 
protein 
N   
Overexpression  yrbL  PHM  predicted protein  N   
Overexpression  entS  RIF  enterobactin efflux transporter  Y 
An entS insertion mutant has increased susceptibility 
to mitomycin C (Han et al., 2010). 
Overexpression  gadE  RIF 
'Glutamic acid decarboxylase' DNA-
binding transcriptional activator 
Y 
gadE activates the glutamic acid decarboxylase 
(GAD) acid resistance system, and multi-drug efflux 
genes (Tucker et al., 2003). 
Overexpression  gfcC  RIF  conserved protein  N   
Overexpression  nuoI  RIF 
NADH:ubiquinone oxidoreductase, 
chain I 
N   
Overexpression  cynS  SCM  cyanase  N 
cynS may function in detoxification of cyanate 
(Anderson et al., 1990).
Overexpression  nudB  SCM, SMX 
dihydroneopterin triphosphate 
pyrophosphohydrolase 
N 
nudB catalyzes the first committed step in the 
synthesis of folate (Suzuki and Brown, 1974). 
Overexpression  pyrG  SCM, SMX  CTP synthetase  N   
Overexpression  ydiZ  SCM  predicted protein  N   
Overexpression  ykfF  SCM  predicted protein  N   
Overexpression  ymgG  SCM  predicted protein  N   
Overexpression  dksA  SMX 
RNA polymerase-binding 
transcription factor 
N 
While dksA overexpression resists SMX, dksA 
deletion resists RIF  
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resistance? 
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Overexpression  puuP  SPX 
proton dependent putrescine 
transporter 
N   
Overexpression  fabI  TCL  enoyl acyl carrier protein reductase  Y  fabI is the target of Triclosan (Heath et al., 1998). 
Overexpression  folA  TMP  dihydrofolate reductase  Y 
folA is the target of Trimethoprim (Miovic and Pizer, 
1971). 
Overexpression  folM  TMP 
dihydromonapterin reductase / 
dihydrofolate reductase 
Y 
folM is a dihydromonapterin reductase with weak 
activity as a dihydrofolate reductase (Giladi et al., 
2003). While folM over-expression confers 
trimethoprim resistance, folM deletion confers 
sulfonamide resistance. 
Overexpression  creA  VAN  conserved protein  N   
Deletion  ddpF  AMK 
putative ATP-binding component of 
an ABC transporter
N 
While ddpF overexpression resists CFS, CLX, MEC, 
PHD, ddpF deletion resists AMK
Deletion  gnsA  AMK 
predicted regulator of 
phosphatidylethanolamine synthesis 
N   
Deletion  pheM  AMK 
phenylalanyl-tRNA synthetase 
operon leader peptide 
N   
Deletion  ydjI  AMK  predicted aldolase  N   
Deletion  sbmA  BLM  peptide antibiotic transporter  Y 
Loss of sbmA function confers resistance to proline-
rich antimicrobial peptides (Mattiuzzo et al., 2007). 
Deletion  asmA  CFS 
predicted outer membrane protein 
assembly protein 
N 
asmA is required for assembly of the porins through 
which cephalosporins enter the cell (Misra and Miao, 
1995).  
Supplementary Table 3.1. Changes in gene expression that increase antibiotic resistance. (continued) 
1
4
5
 
Change in 
gene 
expression 
Gene 
name 
Drugs resisted  Gene function 
Previously 
associated 
with drug 
resistance? 
Notes 
Deletion  hrpB  CFS  predicted ATP-dependent helicase  N   
Deletion  yceG  CFS, VAN 
predicted aminodeoxychorismate 
lyase
N   
Deletion  cadB  CLI  lysine:cadaverine antiporter  N 
cadB is part of the lysine-dependent acid resistance 
system 4 (Meng and Bennett, 1992). 
Deletion  rpmG  CLI  50S ribosomal subunit protein L33  N   
Deletion  speA  CLI  biosynthetic arginine decarboxylase  N 
speA catalyzes the first step in putrescine 
biosynthesis (Wu and Morris, 1973). 
Deletion  speB  CLI  agmatinase  N 
speB catalyzes the second step in putrescine 
biosynthesis (Satishchandran and Boyle, 1986). 
Deletion  lon  CLX 
DNA-binding, ATP-dependent 
protease 
Y 
Loss of lon function stabilizes marA to confer 
antibiotic resistance (Nicoloff et al., 2006). 
Deletion  ompF  CLX, FOX  outer membrane porin F  Y 
ompF is the primary route of cell entry for many 
beta-lactams, particularly cephalosporins (Nikaido, 
1989). 
Deletion  ompR  CLX, FOX  OmpR response regulator  Y 
ompR is the transcriptional activator of ompF; loss of 
ompR prevents synthesis of ompF (Tsui et al., 1988). 
Deletion  atpB  CRB 
ATP synthase F0 complex - a 
subunit 
N   
Deletion  atpE  CRB 
ATP synthase F0 complex - c 
subunit 
N   
Deletion  cpxA  CRB  CpxA sensory histidine kinase  N 
cpxA is part of the stress response pathway to cell 
envelope damage (Pogliano et al., 1997). 
Deletion  rnhA  ERY  RNase HI  N    
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Deletion  sulA  ERY  SOS cell division inhibitor  N   
Deletion  ycbZ  ERY, SPR  putative ATP-dependent protease  N   
Deletion  fepB  MEC  ferric enterobactin ABC transporter  N   
Deletion  fepC  MEC  ferric enterobactin ABC transporter  N   
Deletion  fepG  MEC  ferric enterobactin ABC transporter  N   
Deletion  fes  MEC  enterochelin esterase  N 
fes hydrolyzes ferric enterobactin (Langman et al., 
1972).
Deletion  glnD  MEC  uridylyltransferase  N   
Deletion  pdxA  MEC 
4-hydroxy-L-threonine phosphate 
dehydrogenase, NAD-dependent 
N 
pdxA is required for pyridoxal phosphate synthesis 
(Lam et al., 1992). 
Deletion  rodZ  MEC 
transmembrane component of 
cytoskeleton 
N 
rodZ interacts with the target of mecillinam (mrdA) 
through the MreB cytoskeleton (Bendezu et al., 
2009). 
Deletion  ybjI  MEC  FMN phosphatase  N 
ybjI possesses phosphatase activity against pyridoxal 
phosphate (Kuznetsova et al., 2006). 
Deletion  dbpA  NIT 
ATP-dependent RNA helicase, 
specific for 23S rRNA 
N   
Deletion  lpcA  NIT 
D-sedoheptulose 7-phosphate 
isomerase 
N 
lpcA catalyzes the first step in the synthesis of a core 
component of lipopolysaccharide; lpcA deletion 
confers sensitivity to some antibiotics by increasing 
cell permeability (Tamaki et al., 1971).   
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Deletion  nfsA  NIT  NADPH nitroreductase  Y 
nfsA is required to activate nitrofurantoin to toxic 
reactive species, and so nfsA deletion confers 
nitrofurantoin resistance (McCalla et al., 1978). 
Deletion  pstC  NIT 
phosphate ABC transporter -
membrane subunit
N   
Deletion  rfaC  NIT 
ADP-heptose:LPS 
heptosyltransferase I 
N 
rfaC transfers heptose onto lipopolysaccharide 
(Kadrmas and Raetz, 1998) 
Deletion  rfaD  NIT 
ADP-L-glycero-D-mannoheptose-6-
epimerase 
N 
rfaD catalyzes a step in the synthesis of 
lipopolysaccharide (Kneidinger et al., 2002). 
Deletion  sspA  NIT  stringent starvation protein A  N   
Deletion  ybjC  NIT  predicted inner membrane protein  N 
ybjC is co-transcribed with nfsA (Paterson et al., 
2002). Polar effects on nfsA are a likely mechanism of 
resistance to nitrofurantoin. 
Deletion  ratA  PHM 
toxin of a predicted toxin-antitoxin 
pair
N   
Deletion  ubiF  PHM 
2-octaprenyl-3-methyl-6-methoxy-
1,4-benzoquinone hydroxylase 
Y 
uniF catalyzes a step in the ubiquinone biosynthesis 
pathway. Previously identified as a phleomycin 
resistant mutant (Collis and Grigg, 1989). 
Deletion  ubiG  PHM 
bifunctional 3-demethylubiquinone-
8 3-O-methyltransferase and 2-
octaprenyl-6-hydroxyphenol 
methylase
Y 
ubiG catalyzes a step in the ubiquinone biosynthesis 
pathway. ubiG deletion produces a similar defect to a 
Phleomycin-resistant mutation in ubiF 
Deletion  ubiH  PHM 
2-octaprenyl-6-methoxyphenol 
hydroxylase 
Y 
ubiH catalyzes a step in the ubiquinone biosynthesis 
pathway. ubiH deletion produces a similar defect to a 
Phleomycin-resistant mutation in ubiF  
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Deletion  ycgB  PHM  conserved protein  N   
Deletion  ymgG  PHM  predicted protein  N   
Deletion  dksA  RIF 
RNA polymerase-binding 
transcription factor DksA 
N 
While dksA overexpression resists SMX, dksA 
deletion resists RIF 
Deletion  marC  RIF  predicted transporter  N   
Deletion  ptsN  RIF 
phosphotransferase system enzyme 
IIA, regulation of potassium 
transport 
N   
Deletion  rlmL  RIF 
fused dual 23S rRNA 
methyltransferase 
N   
Deletion  yfgH  RIF 
predicted outer membrane 
lipoprotein 
N   
Deletion  ccmH  SCM, SMX  cytochrome c biogenesis protein  N   
Deletion  folM  SCM, SMX 
dihydromonapterin reductase / 
dihydrofolate reductase 
Y 
While folM over-expression confers trimethoprim 
resistance, folM deletion confers sulfonamide 
resistance. A folM deletion has been previously 
observed to confer sulfonamide resistance (Girgis et 
al., 2009). 
Deletion  folX  SCM, SMX 
dihydroneopterin triphosphate 2'-
epimerase 
Y 
A folX deletion has been previously observed to 
confer sulfonamide resistance (Girgis et al., 2009). 
Deletion  ybiP  SPR 
predicted hydrolase, inner 
membrane 
N    
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Deletion  ygeO  SPR  predicted protein  N 
ygeO is involved in the production of Extracellular 
Death Factor (Kolodkin-Gal et al., 2007). 
Deletion  ymfJ  SPR  predicted protein  N   
Deletion  rsxC  TMP  member of SoxR-reducing complex  Y 
rsxC deletion produces constitutive transcription of 
sox operon (Koo et al., 2003). 
Deletion  dacA  VAN 
D-alanyl-D-alanine 
carboxypeptidase IA (PBP5) 
N 
dacA is involved in production of the cellular target 
of vancomycin binding (D-alanyl-D-alanine). dacA 
deletion confers increased beta-lactam susceptibility 
(Sarkar et al., 2010).
Deletion  ycgB  PHM  conserved protein  N    
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Supplementary Figure 3.2. Measurement of IPTG-induced transcription of antibiotic 
resistance genes by beta-galactosidase assays. The pCA24N plasmid used to express Open 
Reading Frames in the ASKA library was engineered to express lacZ, and transformed into 
BW25113. Liquid cultures of this strain were prepared as for growth rate assays, across a 
gradient of IPTG concentrations. In early log phase, promoter activity was measured in Miller 
Units by a kinetic beta-galactosidase assay (black points). The resulting data is well described 
by two straight lines on a double-log plot (gray lines). From this data, eight IPTG 
concentrations were chosen for the growth rate assays in Figures 3 and 4, that produced 
evenly log-distributed amounts of promoter activity (in Miller Units) over a 50-fold dynamic 
range (red crosses).  
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Supplementary Figure 3.3. Non-optimal use of antibiotic resistance genes under antibiotic 
stress. Microtiter plates containing 2-dimensional gradients of IPTG and antibiotic were 
inoculated with either a wildtype strain (WT = BW25113 pCA24N-ΔpT5lac-yfp pCSλ), a 
strain lacking a gene of interest (Δgene = BW25113 gene::FRT pCA24N-ΔpT5lac-yfp pCSλ), 
or a strain with experimentally controlled expression of the gene of interest (BW25113 
gene::FRT pCA24N-gene pCSλ). Plates were incubated at 30°C in a scintillation counter and 
growth rates were measured based on bioluminescence, generated by the pCSλ plasmid 
(Methods). a, The use of marA and soxS was measured in a panel of 9 antibiotics. b, The use 
of ampC was measured in ampicillin and cephalexin, and the use of sbmC was measured in 
phleomycin.  
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Supplementary Figure 3.3 (continued).   
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Supplementary Figure 3.3 (continued).   
  154
Supplementary Material for Chapter 4. 
The dependence of antibiotic resistance on target expression 
 
 
 
Supplementary Figure 4.1. Measurement of IPTG-induced transcription of drug target 
genes by beta-galactosidase assays. A strain was constructed where lacZ was encoded in 
place of a drug target gene (BW25113 pCA24N-lacZ). Liquid cultures of this strain were 
prepared as for growth rate assays, across a gradient of IPTG concentrations. In early log 
phase, promoter activity was measured in Miller Units by a kinetic beta-galactosidase assay 
(black points). The resulting data is well described by two straight lines on a double-log plot 
(gray lines). From this data, eight IPTG concentrations were chosen for the growth rate assays 
in Figure 1b, that produced evenly log-distributed amounts of promoter activity (in Miller 
Units) over a 50-fold dynamic range (red crosses).  
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Supplementary Figure 4.2. Mass-action kinetic models reveal the relations between 
enzyme concentration and drug resistance. 
In sections a and b we first derive the relation between drug target over-expression and drug 
resistance for the simple model shown in Figure 4.2a. In sections c, d, e and f we show that 
mass-action kinetic models of competitive and non-competitive inhibition produce identical 
results to the initial simple models. 
 
(a) Simple model of a drug that solely inhibits an enzyme 
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Supplementary Figure 4.2. (continued) 
Let [E]total = ( Ewt + Eadditional ). 
Solve for IC50, first without considering fitness costs of additional enzyme production: 
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Supplementary Figure 4.2. (continued) 
Solve for IC50, considering fitness costs of additional enzyme production, cost(Eadditional): 
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Supplementary Figure 4.2. (continued) 
(b) Simple model of a drug that induces a harmful enzyme-catalyzed reaction.  
The mechanism of inhibition modeled here can result in a depletion of substrate S, and so to 
model this effect S is treated as a dynamical variable, synthesized at rate α. 
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Supplementary Figure 4.2. (continued) 
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Supplementary Figure 4.2. (continued) 
Let [E]total = ( Ewt + Eadditional ). Note that in contrast to the model of enzyme inhibition in 
Supplementary Figure 4.2a, this substitution now has no effect on reaction rate. 
 
Solve for IC50, first without considering fitness costs of additional enzyme production: 
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Solve for IC50, considering fitness costs of additional enzyme production, cost(Eadditional): 
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Supplementary Figure 4.2. (continued) 
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Supplementary Figure 4.2. (continued) 
(c). Competitive enzyme inhibition 
Example: E = Dihydrofolate reductase (DHFR), S = dihydrofolic acid, P = tetrahydrofolic 
acid, I = trimethoprim (Supplementary Figure 4.4b). 
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Supplementary Figure 4.2. (continued) 
Let [E]total = ( Ewt + Eadditional ). 
Solve for IC50, first without considering fitness costs of additional enzyme production: 
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Supplementary Figure 4.2. (continued) 
Let [E]total = ( Ewt + Eadditional ). 
Solve for IC50, considering fitness costs of additional enzyme production, cost(Eadditional): 
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Supplementary Figure 4.2. (continued) 
(d). Non-competitive enzyme inhibition 
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The remainder of the derivation is identical to that in Supplementary Figure 4.2a, yielding 
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depending on the absence or presence of fitness costs for drug target over-expression.   
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Supplementary Figure 4.2. (continued) 
(e). Competitive substrate damage 
The mechanism of inhibition modeled here can result in a depletion of substrate S2, and so to 
model this effect S2 is treated as a dynamical variable, synthesized at rate α; while S1 is treated 
as a constant. 
Example: E = Dihydropteroate synthase (DHPS), S1 = para-aminobenzoic acid (PABA), S2 = 
pteridine diphosphate, P = dihydropteroate, I = sulfamethoxazole, I-S2 = dihydropterin-
sulfamethoxazole (Supplementary Figure 4.4a). 
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Supplementary Figure 4.2. (continued) 
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Supplementary Figure 4.2. (continued) 
Let [E]total = ( Ewt + Eadditional ). 
Solve for IC50, considering fitness costs of additional enzyme production, cost(Eadditional): 
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Supplementary Figure 4.2. (continued) 
(f). Non-competitive substrate damage 
The mechanism of inhibition modeled here can result in a depletion of substrate S, and so to 
model this effect S is treated as a dynamical variable, synthesized at rate α. 
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Supplementary Figure 4.2. (continued) 
The remainder of the derivation is identical to that in Supplementary Figure 4.2b, yielding
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depending on the absence or presence of fitness costs for drug target over-expression.
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Supplementary Figure 4.3. Wildtype enzyme abundance quantitatively affects the 
resistance obtained upon drug target over-expression. Over-expression of a non-costly 
target gene of an enzyme inhibitor confers increased drug resistance according to the 
equation IC50/IC50wt = 2×(Ewt+Eadditional) / Ewt  −  1 (Supplementary Figure 4.3a, b). 
Consequently, variation in Ewt affects the change in resistance for a given value of Eadditional: 
when plotted against log(Eadditional) the response curve retains its shape but is translated along 
the log(Eadditional) axis by the log of the ratio of Ewt values. This phenomenon explains the 
quantitative difference in resistance between trimethoprim and triclosan on the over-
expression of each drug's target (DHFR and ENR, respectively). Known differences in Ewt 
explain most of the observed variation: Taniguchi et al measured wildtype protein 
abundances in E. coli with single-molecule sensitivity using fluorescent protein 
fusions(Taniguchi et al., 2010), and measured the mean single-cell abundance of DHFR (folA) 
as 38 proteins / cell, while ENR (fabI) was more highly expressed at 342 proteins / cell 
(Supplementary Table 6 of (Taniguchi et al., 2010). While log10(Ewt ENR / Ewt DHFR) ≈ 1,  the 
measured curves (IC50/IC50wt)DHFR and (IC50/IC50wt)ENR differ by 1.5 units on the 
log10(Eadditional) axis (Figure 4.2b). The additional difference of 0.5 may be explained by 
differences in transcript stability or translation efficiency between the exogenous (plasmid-
expressed) transcript and the endogenous (chromosomal) transcript. An altered number of 
proteins produced per exogenous transcript can be characterized by a coefficient in front of 
Eadditional, which is mathematically equivalent to variation in Ewt and thus results in a shift along 
the log(Eadditional) axis. One feature of the response to ENR over-expression is still not  
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explained by this theory: an elevated baseline level of resistance, conferred by carriage of the 
ENR-expressing plasmid even without IPTG (Figure 4.1b). This effect, and a similar effect for 
DNA Gyrase and Topo IV (reduced baseline resistance), can be explained by an elevated 
baseline transcription of these genes from weak internal promoters (Supplementary Figure 
4.5). 
 
 
 
 
Supplementary Figure 4.3. Wildtype enzyme abundance quantitatively affects the 
resistance obtained upon drug target over-expression. (Continued) 
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Supplementary Figure 4.4. Sulfonamides and trimethoprim inhibit their targets by 
different molecular mechanisms. (a) Sulfonamide class antibiotics, such as 
sulfamethoxazole, compete with para-aminobenzoic acid for binding to Dihydropteroate 
synthase (DHPS). When sulfonamides bind to DHPS they do not inhibit catalysis, but are 
covalently linked by DHPS to the substrate pteridine diphosphate. This substrate-diverting 
reaction constitutes a distinction from competitive inhibition that profoundly changes the 
relation between enzyme concentration and drug resistance (Supplementary Figure 4.2) (b) 
Trimethoprim competes with dihydrofolic acid for binding to Dihydrofolate reductase 
(DHFR), and exemplifies the traditional concept of a competitive enzyme inhibitor: DHFR 
has no catalytic activity when bound by trimethoprim.  
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Supplementary Figure 4.4. Sulfonamides and trimethoprim inhibit their targets by 
different molecular mechanisms. (Continued)  
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Supplementary Figure 4.5. Small differences in baseline drug resistance can be explained 
by weak internal promoters in drug target genes. Plasmids encoding the drug target genes 
ENR, Gyrase, and Topo IV induce small changes in resistance that do do not appear to be 
caused by basal IPTG-regulated transcription (Supplementary Figure 4.1), since this baseline 
change in resistance does not change further until a greater than 5-fold increase in IPTG-
induced transcription (Figure 4.1b). These effects may be explained by weak internal 
promoters in these drug target genes, that will induce a baseline level of additional 
transcription that is not IPTG-responsive. This figure demonstrates the theoretical responses 
to ENR (h–c–), Gyrase (h+c+  lethal) and Topo IV (h+c+  partial) in the presence of a weak 
internal promoter. Small amounts of additional drug target production have the effect of 
inducing small changes in drug resistance; positive for h–c– and negative for h+c+; that persist 
even as IPTG-regulated Eadditional approaches zero. In the examples shown here, the h–c– gene 
(compare to ENR, Figure 4.1b) contains an internal promoter of 0.5% of the wildtype 
promoter strength. As this gene is encoded on a plasmid with, conservatively, 50 copies per 
cell(Kitagawa et al., 2005; Lutz and Bujard, 1997), this 0.5% activity per gene copy leads to a 
baseline synthesis of 25% of Ewt, and consequently a measurable increase in baseline IC50. 
This quantitative calibration (internal promoter = 0.5% of Ewt) is made possible by the relative 
increase in drug resistance; such an estimation is not possible for genes that only incur costs, 
not protection (e.g. Gyrase and Topo IV). 
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Supplementary Figure 4.5. Small differences in baseline drug resistance can be explained 
by weak internal promoters in drug target genes. (Continued)  
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